

MAHARASHTRA MEDICAL GOODS PROCUREMENT AUTHORITY

Expression of Interest (EOI) for Market Assessment of Original Manufacturers and Authorized Importers for Supply of Injectables (Year 2026-27)

**EOI reference No: E-290/MMGPA/ EOI for Injectables
(2026-27)**

1st Floor, Aarogya Bhawan St. George's Hospital Compound,
Near C.S.M.T. Railway Station, Mumbai - 400 001.
Maharashtra

Website: <http://mahatenders.gov.in>

Email: maha.mmghpa2023@gmail.com Phone : 022-22717527

Table of Contents

Table of Contents.....	2
Disclaimer	4
Abbreviations and Glossary	6
Notice and Schedule Inviting Expression of Interest (EOI)	7
EOI Notice	7
Section 1: Introduction	8
Section 2: General Definitions	9
Section 3: General Terms and Conditions	10
3.1 Responsibility of verification of contents of EOI	10
3.2 Acknowledgement of the Responder	10
3.3 Period of Validity of EOI	10
3.4 Nature of the Expression of Interest.....	10
3.5 Responsibility of EOI Respondents	11
3.6 Submission of EOI Responses	11
3.7 Clarifications and Amendments.....	11
3.8 Conflict of Interest	12
3.9 Fraudulent and Corrupt Practices.....	12
3.10 Confidentiality	12
3.11 Governing Law	12
3.12 Respondents Information	12
3.13 Manufacturing/Importing and Product Permissions	14
3.14 Delivery Capability.....	14
3.15 Respondent Classification.....	15
3.16 Eligibility Criteria	15
Appendix A: Schedule of Requirements	23
Appendix B: Checklist	51
Annexure 1: Technical Specifications and Compliance	53
Annexure-2: Undertaking by EoI Respondent	55
Annexure-3: Proforma for Production and Sale Statement	57
Annexure 4: Details of Manufacturing Unit.....	58
Annexure-4 (A): Proof of Distribution Network.....	61
Annexure-5: Details of Items Quoted with Drug Code	62
Annexure 6: Annual Turnover Statement for Three Years	63
Annexure-7: Format for Power of Attorney for signing of EOI.....	65

Annexure-8: Undertaking for Non-blacklisting	67
Annexure- 9: Litigation Affidavit.....	68
Annexure-10: Litigation Affidavit.....	69
Annexure 11: Delivery and Supply Capability.....	70
Annexure 11 (a) : Delivery Acceptance Certificate.....	71
Annexure 12: Respondent Classification Details	72

Disclaimer

This Expression of Interest (EOI) Document is not an agreement and is neither an offer nor invitation by the MMGPA to the prospective EOI Responders or any other person. The purpose of this Expression of Interest (EOI) Document is to invite interested and eligible entities to provide information relating to their regulatory status, manufacturing capability, quality systems, market presence, and related parameters, solely to enable MMGPA to undertake a market assessment and planning exercise in connection with any potential future procurement of Injectables.

This Expression of Interest (EOI) Document contains information, statements, and indicative details prepared by MMGPA solely for the purpose of facilitating a broad market assessment and planning exercise in relation to the potential future procurement of Injectables. Such information and statements are based on assumptions, preliminary assessments, and internal considerations and are not intended to be exhaustive or definitive. This EOI Document may not address the specific circumstances, operational capacities, or regulatory positions of every interested entity, and MMGPA, its employees, or advisors do not undertake to consider the individual requirements of each person or entity reviewing or responding to this document. The information provided herein may be subject to change and may not be complete, accurate, or current in all respects. Each EOI Respondent is therefore advised to conduct its own assessment, verification, and analysis of the information contained in this EOI Document and to seek independent professional or technical advice as it considers appropriate.

Information provided in this Expression of Interest (EOI) Document to the EOI Responder(s) is on a wide range of matters, some of which may depend upon interpretation of law. The information given is not intended to be an exhaustive account of statutory requirements and should not be regarded as a complete or authoritative statement of law. The MMGPA accepts no responsibility for the accuracy or otherwise for any interpretation or opinion on law expressed herein.

The MMGPA, its employees and advisors make no representation or warranty and shall have no liability to any person, including any EOI Responder(s) under any law, statute, rules or regulations or tort, principles of restitution or unjust enrichment or otherwise for any loss, damages, cost or expense which may arise from or be incurred or suffered on account of anything contained in this Expression of Interest (EOI) Document or otherwise, including the accuracy, adequacy, correctness, completeness or reliability of the Expression of Interest (EOI) Document and any assessment, assumption, statement or information contained therein or deemed to form part of this Expression of Interest (EOI) Document or arising in any way for participation in this Expression of Interest (EOI) Document.

The MMGPA may, in its absolute discretion but without being under any obligation to do so, update, amend or supplement the information, assessment or assumptions contained in this Expression of Interest (EOI) Document.

The EOI Responder(s) shall bear all its costs associated with or relating to the preparation and submission of its EOI Response including but not limited to preparation, copying, postage, delivery fees, expenses associated with any demonstrations or presentations which may be required by the MMGPA, or any other costs incurred in connection with or relating to its EOI Response. All such costs and expenses will remain with the EOI Responder(s) and the MMGPA shall not be liable in any manner whatsoever for the same or for any other costs or other expenses incurred by a EOI Responder(s) in preparation or submission of the EOI Response, regardless of the conduct or outcome of the responding process. The MMGPA also accepts no liability of any nature whether resulting from negligence or otherwise howsoever caused arising from reliance of any EOI Responder(s) upon the statements contained in this Expression of Interest (EOI) Document.

MMGPA shall not be responsible or liable for any costs, expenses, or losses incurred by EOI Respondents in connection with preparation or submission of EOI Responses, regardless of the outcome of the EOI process. Participation in this Expression of Interest (EOI) shall not confer any right or entitlement on the EOI Respondents to participate in any subsequent procurement process.

MMGPA reserves the right to independently determine the eligibility criteria, qualification requirements, and procurement strategy in any future tender process, without any reference to or obligation arising from this EOI.

Abbreviations and Glossary

Abbreviations	Description
BET	Bacterial Endotoxin Test
BIS	Bureau of Indian Standards
BP	British Pharmacopeia
CA	Chartered Accountant
CLA	Central Level Authority
COPP	Certificate of Pharmaceutical Products
CT	Clinical Trials
DCGI	Drug Controller General of India
DMER	Directorate of Medical Education & Research
DPCO	Drug Price Control Order
DPIIT	Department for Promotion of Industry and Internal Trade
ESIC	Employees State Insurance Corporation
FDA	Food and Drug Administration
FEMA	Foreign Exchange Management Act 1999
GMP	Good Manufacturing Practices
G.R.	Government Resolution
GST	Goods and Services Tax
GS1	Global Standards1
HBPCL	Haffkine Bio-Pharmaceutical Corporation Limited
IEC	Import Export Code
IP	Indian Pharmacopeia
ISI	Indian Standards Institute
I.V.	Intra Venous
LLP	Limited Liability Partnership
MCGM	Municipal Corporation of Greater Mumbai
MDR	Medical Device Rules
MMGPA	Maharashtra Medical Goods Procurement Authority
MRP	Maximum Retail Price
MSC	Market Standing Certificate
MSEs	Micro and Small Enterprises
NABL	National Accreditation Board for Laboratories
NSQ	Not of Standard Quality
NPPA	National Pharmaceutical Pricing Authority
OEM	Original Equipment Manufacturer
PAN	Permanent Account Number
PoA	Power of Attorney
PVC	Poly Vinyl Chloride
PVdC	Poly Vinylidene Chloride
SLA	State Level Authority
SSI	Small Scale Industries
UDIN	Unique Document Identification Number
USP	United States Pharmacopeia
WHO	World Health Organization

Notice and Schedule Inviting Expression of Interest (EOI)

EOI Notice

The Maharashtra Medical Goods Procurement Authority (MMGPA) invites Expressions of Interest (EOI) from eligible Original Manufacturers (OEMs) and their Authorized Importers for assessing market capability, regulatory compliance, manufacturing capacity, and delivery capability for supply of Injectables to public health institutions in the State of Maharashtra.

This EOI is a non-binding, pre-procurement exercise and does not constitute a tender or offer of contract. No price submissions, financial offers, or securities are required at this stage.

The objective of this EOI is to assess the number of eligible and capable OEMs and Authorized Importers available for the listed Injectables and their readiness to participate in future procurement processes.

The information collected through this EOI will be used for planning future procurement strategies. MMGPA reserves the right to initiate or not initiate any subsequent tender or rate contract process without any obligation to the EOI respondents.

Only Original Manufacturers or their Authorized Importers are eligible to participate. Traders, distributors, and other intermediaries are not permitted.

Interested entities meeting the eligibility conditions are invited to submit their EOI responses within the timelines specified in this document.

EOI responses must be submitted within fifteen (15) days from the date of publication of this EOI. Late submissions shall not be accepted.

All response-related activities, including downloading of documents and submission of responses, shall be governed by the schedule indicated below.

EOI Response Schedule

No.	Activity	Date & Time
1	Publication of Notice Inviting Expression of Interest (EOI)	From 27.05.2026 , 11:00 AM
2	Last date and time for submission of EOI Responses	dt.10.06.2026 at 3:00 PM
3	Opening of EOI Responses (Technical & capability only, No price information shall be submitted)	dt. 11.06.2026 at 3:00 PM
4	EoI Clarification Meeting	From 03.06.2026 , 02:00 PM
5	Address for communication	Meeting Hall, 1st Floor, Aarogya Bhawan, St. Georges Hospital Compound, Near CSMT Railway Station, Mumbai- 400 001

Sd/-

CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY
MUMBAI

Section 1: Introduction

Maharashtra Medical Goods Procurement Authority (MMGPA), Mumbai has been formed as per the Maharashtra Medical Goods Procurement Authority Act 2023 (Mah. Act No. XIII of 2023) (“Act”).

MMGPA works as a single point procurement authority of certain medical goods and execution of turnkey projects with highest standards of transparency, fairness, equity and for timely supply at optimum and uniform rates and of desired quality and quantity for the Public Health Department, Medical Education & Drug Department of Government of Maharashtra and other departments as mentioned in the said Act.

To meet the objective of the Act, MMGPA in exercise of its powers under section 36 of the Act issued the regulations named, Maharashtra Medical Goods Procurement Authority Regulations, 2025 as amended from time to time.

- 1.1 All related activities (process) like EOI downloading and response submission will be governed by the EOI Schedule.
- 1.2 All activities of this EOI are carried out online on website <https://mahatenders.gov.in>. The EOI is uploaded on Government of Maharashtra, (GoM) e-tendering website <https://mahatenders.gov.in> and has to be downloaded as well as filled up and submitted online only.
- 1.3 No commitment is made by MMGPA regarding procurement of any quantity pursuant to this EOI, and the Authority reserves the right to modify, expand, curtail, or altogether omit any items or quantities in any subsequent procurement process, if undertaken
- 1.4 EOI process related Queries can be sent on email – eproc.support@maharashtra.gov.in /Help: The 24 x 7 Toll Free Telephonic Help Desk Number 1800-3070-2232. / Mobile: +91-7878107985, +91-7878107986, +91-7878007972 and +91-7878007973.

Sd/-
CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY
MUMBAI

Section 2: General Definitions

For the purposes of this Expression of Interest (EOI) Document, and unless the context otherwise requires, the following terms shall have the meanings assigned to them below:

- 2.1 **“Applicable Laws”** Means all laws, statutes, rules, regulations, notifications, guidelines, and policies in force in India as issued by the Government of India or the Government of Maharashtra, including but not limited to the Drugs and Cosmetics Act, 1940 and Rules thereunder, Medical Device Rules, 2017, New Drugs and Clinical Trials Rules, 2019, NPPA/DPCO provisions, and other applicable regulatory requirements, as amended from time to time.
- 2.2 **“Authority” or “MMGPA”** Means the Maharashtra Medical Goods Procurement Authority, established under the Maharashtra Medical Goods Procurement Authority Act, 2023.
- 2.3 **“Expression of Interest” or “EOI”** Means this non-binding, pre-procurement process initiated by MMGPA to solicit information regarding market capability, regulatory compliance, manufacturing capacity, and quality systems from eligible entities.
- 2.4 **“EOI Document”** Means this document, including all sections, appendices, annexures (if any), and amendments issued by MMGPA in connection with the Expression of Interest.
- 2.5 **“EOI Response”** Means the information and declarations submitted by an EOI Respondent in response to this EOI Document, limited to technical, regulatory, manufacturing, and capability-related information.
- 2.6 **“EOI Respondent”** Means any manufacturer or importer who submits an EOI Response pursuant to this EOI Document.
- 2.7 **“Conflict of Interest”** Means any situation in which an EOI Respondent has interests that could improperly influence its participation in the EOI process, including but not limited to relationships that compromise fairness, transparency, or objectivity.
- 2.8 **“Fraudulent or Corrupt Practices”** Means misrepresentation, concealment of facts, submission of false or forged documents, or any attempt to influence the EOI process improperly.
- 2.9 **“Government”** Means the Government of India or the Government of Maharashtra, as applicable.

Interpretation Words and expressions used but not defined in this EOI Document shall have the meanings assigned to them under Applicable Laws.

Note: The words and expressions used in this EOI, but not defined, shall have the same meaning as respectively assigned to them under the prevailing Applicable Laws.

Section 3: General Terms and Conditions

This section deals with the general conditions of the EOI and contains the following terms & conditions governing the EOI.

3.1 Responsibility of verification of contents of EOI

- 3.1.1 It shall be the responsibility of the EOI Responders to read/examine all instructions, forms, terms, conditions, specifications, schedules, appendix, annexures and other provisions contained in the Expression of Interest (EOI) Document, including any addendum or corrigendum issued thereunder prior to submission of the response.
- 3.1.2 Responders shall ensure that all required documents as specified in **Appendix A (Checklist)** are duly uploaded.

3.2 Acknowledgement of the Responder

- 3.2.1 It shall be deemed that by submitting the EOI, the Responder has:
- i. examined the EOI Document and understood its contents.
 - ii. received all relevant information available from MMGPA
 - iii. acknowledged and agreed that inadequacy, lack of completeness or incorrectness of information provided in the Expression of Interest (EOI) Documents shall not be a basis for any claim for compensation, damages or extension of time.
 - iv. acknowledged that it does not have a Conflict of Interest as per Clause 3.9 and
 - v. agreed to be bound by the provisions and undertakings provided by it under and in terms hereof.

MMGPA shall not be liable for any omission, mistake or error in respect of any of the above or on account of any matter or thing arising out of or concerning or relating to the EOI or its Responding process, including any error or mistake therein or in any information or data given by MMGPA.

3.3 Period of Validity of EOI

- 3.3.1 The EOI Response submitted pursuant to this document shall remain valid for the purpose of this EOI process only until completion of the EOI exercise or initiation of any subsequent procurement process, whichever is earlier.

3.4 Nature of the Expression of Interest

- 3.4.1 The information received pursuant to this EOI shall be used by MMGPA only for:
- a) market assessment and planning,
 - b) identification of technically and regulatorily suitable entities, and
 - c) formulation of future procurement strategies, if any.
- 3.4.2 This Expression of Interest (EOI) is a non-binding, pre-procurement exercise issued solely for the purpose of assessing market capability, regulatory compliance, manufacturing capacity, and quality systems of eligible entities.
- 3.4.3 Submission of an EOI Response does not constitute a bid, tender, or offer, and does not create any contractual, financial, or legal obligation on either MMGPA or the EOI Respondent.

- 3.4.4 MMGPA reserves the right to initiate or not initiate any subsequent procurement process, including a tender or RFP, without assigning any reason.
- 3.4.5 The EOI is intended to assess the number of eligible and capable Original Manufacturers and Authorized Importers available for each essential medicine/item and their readiness to participate in future procurement processes.

3.5 Responsibility of EOI Respondents

- 3.5.1 Each EOI Respondent shall:
- a) carefully examine the EOI Document and all instructions therein;
 - b) ensure that all information and documents submitted are true, accurate, and complete to the best of its knowledge;
 - c) satisfy itself regarding the scope, intent, and implications of the EOI.
 - d) Any misrepresentation, concealment, or submission of false information may result in rejection of the EOI Response.
- 3.5.2 Respondents shall provide accurate information regarding:
- (a) availability of medicines/item(s) against the provided list,
 - (b) manufacturing/import capacity,
 - (c) indicative delivery timelines.

3.6 Submission of EOI Responses

- 3.6.1 EOI Responses must be submitted within fifteen (15) days from the date of publication of the EOI. Late submissions shall not be accepted.
- 3.6.2 The EOI Response shall be limited to technical, regulatory, manufacturing, and capability-related information only.
- 3.6.3 No price bids, financial offers, bid securities, earnest money deposits, or payments of any kind are required or permitted at the EOI stage.

3.7 Clarifications and Amendments

- 3.7.1 EOI Respondents may seek clarification, within the timelines specified in the EOI Schedule.
- 3.7.2 MMGPA may, at its discretion:
- a) **issue clarifications,**
 - b) **amend the EOI Document, or**
 - c) **modify the EOI Schedule.**
- 3.7.3 All such clarifications or amendments shall form an integral part of the EOI Document.

3.8 Conflict of Interest

- 3.8.1 EOI Respondents shall disclose any actual or potential conflict of interest that may affect their participation in the EOI process.
- 3.8.2 MMGPA reserves the right to reject an EOI Response where a conflict of interest is found to compromise fairness, transparency, or objectivity.

3.9 Fraudulent and Corrupt Practices

- 3.9.1 EOI Respondents shall observe the highest ethical standards during the EOI process.
- 3.9.2 Any attempt to:
- a) misrepresent facts,
 - b) submit forged or misleading documents, or
 - c) improperly influence the EOI process
- 3.9.3 may result in rejection of the EOI Response and may render the entity ineligible for participation in future EOIs issued by MMGPA.

3.10 Confidentiality

- 3.10.1 Information submitted by EOI Respondents shall be treated as confidential to the extent permitted under applicable laws.
- 3.10.2 MMGPA may disclose such information where required by law, regulation, or directions of statutory or judicial authorities.

3.11 Governing Law

This EOI process shall be governed by and construed in accordance with the laws of India.

3.12 Respondents Information

Sr. No.	Document Name / Requirement	Description
1	Drug Manufacturing License	The manufacturing premises of the EOI Respondent 's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The EOI Respondent shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023. Attested photocopy of valid manufacturing drug license with product list approved by Central/State Licensing

Sr. No.	Document Name / Requirement	Description
		Authority for each and every product quoted as per technical specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license. If quoted item is manufactured at different places, Manufacturing License & Performance certificate from all such places from respective Licensing Authority/ State Drug Authority should be enclosed. However, Loan Licensee/ third party licensee are not allowed.
2	WHO-GMP Certificate	WHO-GMP certificate (with product list or COPP) clearly highlighting quoted products.
3	DCGI Permission	Copy of permission from DCGI for “New Drug & Fixed Dose Combination”.
4	Market Standing Certificate	Market Standing Certificate valid for a period of 5 years (i.e., for financial year 2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender within the Bid Due date. The period of Market Standing will be reckoned from the date of issue of Product permission. In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing certificate, as applicable.
5	GST Registration	GST Registration certificate along with copy of last quarter.
6	Incorporation/Registration Certificate	Certificate of Incorporation / Registration of the EOI Respondent .
7	Authorization Letter	Authorization nominating responsible person to attend pre-bid/negotiation meetings.
8	Appendix-A	Schedule of Requirements.
9	Appendix-B	Checklist.
10	Annexure-1	Technical Specifications and Compliance.
11	Annexure-2	Letter Comprising Technical Bid.
12	Annexure-3	Proforma for Production and Sale Statement.
13	Annexure-4	Details of Manufacturing Unit.
13	Annexure-5	Details of Items Quoted with Drug Code.

Sr. No.	Document Name / Requirement	Description
15	Annexure-6	Annual Turnover Statement for three years (2022-23, 2023-24, and 2024-25) along with audited Balance Sheet & P&L Accounts for last 3 years certified by Statutory Auditor/Chartered Accountant with UDIN.
16	Annexure-7	Format of Power of Attorney for signing of Bid (not required for proprietorship).
17	Annexure-8	Affidavit for Non- Blacklisting.
18	Annexure-9	Litigation Affidavit.
19	Annexure-10	Mandate Form.
20	Schedule-4	Schedule for Packing of Drugs and Medicines.
21	Schedule-5	Bar Code & Advance Shipment Notification details.

3.13 Manufacturing/Importing and Product Permissions

- 3.13.1 EOI Respondents shall furnish details of their regulatory status as pharmaceutical manufacturers and/or importers licensed under the provisions of the Drugs and Cosmetics Act, 1940 and the rules made thereunder. Such details may include manufacturing licenses issued by the competent State Licensing Authority (SLA) and/or Central Licensing Authority (CLA), including licenses in Forms 25, 28, 28D, 28E, MD-5, and MD-9, as applicable to the drugs proposed, together with validity or retention particulars.
- 3.13.2 In the case of importers, Respondents shall furnish details of import licenses issued by the Drugs Controller General of India (DCGI), including Forms 10 or 10-A, along with relevant import registrations such as Form 41 or Form MD-15, and associated wholesale licenses such as Forms 20B and/or 21B, wherever applicable.
- 3.13.3 In respect of New Drugs and/or Fixed Dose Combinations, Respondents shall furnish details of import and/or manufacturing permissions obtained under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019, including permissions such as Forms CT-20 and/or CT-23, where applicable.
- 3.13.4 In case of imported products, only one authorized importer per Original Manufacturer per product shall be permitted.
- 3.13.5 Respondents shall also indicate linkage between manufacturing/import approvals and supply capability, including delivery timelines.

3.14 Delivery Capability

- 3.14.1 EOI Respondents shall provide indicative details on:
- (a) production lead time,
 - (b) dispatch timeline,
 - (c) emergency supply capability,

- (d) monthly production capacity,
- (e) warehousing/logistics arrangements in Maharashtra.

3.15 Respondent Classification

3.15.1 EOI Respondents shall provide information on:

- (a) MSME status,
- (b) SC/ST ownership,
- (c) location – within Maharashtra / outside Maharashtra.

3.16 Eligibility Criteria

Sr.No.	Basic Requirement	Specific Requirement	Documents required
1	Registered Legal Entity	The EOI Respondent may be a company or a firm, registered under applicable laws in India (“Respondent”). The Respondent shall be – a. A Private Limited Company or a section 8 Company registered under the Companies Act 1956/2013, b. A Limited Liability Partnership under the Limited Liability Partnership Act 2008 c. Registered with the GST Authorities. d. Should have a valid PAN/TAN number. Proprietorship firms are not allowed to participate in this EOI.	Copy of certificate of incorporation/registration along with charter documents like copy of Memorandum and Articles of Association, and other registration documents according to the nature of entity. Copy of GST Registration certificate issued by GSTN authorities. Copy of PAN/TAN Card.
2	Licenses	The Respondent must have valid manufacturing license/import license for the drugs quoted as per technical specifications in the Tender Documents:	Self-attested copies of original manufacturing license in Form 25, 28, 28-D, 28-E, MD-5, MD-9 etc. approved by the Licensing authority along

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		a. Only manufacturer/ importer (i.e., authorized agent/subsidiary of the foreign manufacturer) will be allowed as Bidder. b. Loan Licensee / third party licensee are not permitted to participate under this Tender Document.	with retention Licenses. Or Self-attested copies of original import license in Form-10 or Form 10-A (as applicable), Form-41, MD-15 etc., and licenses in Form 20B/21B approved by the corresponding licensing authority with retention licenses. Or Self-attested copies of licenses in Form CT-20, Form CT-23 in case of new drugs. Further, during supply of drugs, if the drugs are manufactured at more than one premises, the Bidder shall submit the applicable license such as the manufacturing license, for each such premises mandatorily. Authority letter of the original manufacturer for importing the product for which bid is offered or agreement between foreign manufacturer and importer. The drugs quoted shall be highlighted in the product permission with their respective drug code as mentioned in the Appendix-A (Schedule of Requirement)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
3	Certifications/Registration	WHO-GMP (WHO - Good Manufacturing Practices Certificate) Certificate issued by the licensing authority. The WHO-GMP certificate must not be older than one year from the Bid Due Date in case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Importer should produce WHO-GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted. The manufacturing premises of the Bidder's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The bidder shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023.	For manufacturers, WHO-GMP certificate with product list OR COPP, Quality management System (QMS) as per Medical Devices Rules, 2017 issued by the licensing authority wherever applicable. For importers, labels and product literature of all quoted drug(s) must be uploaded with WHO-GMP or certificate which is at par with WHO-GMP issued by the authorities of exporting countries of their principal manufacturing company or firm. Authority letter from OEM for the offered drug and valid import license issued by licensing authority. Import Export Certificate (IEC Code) for importer.
4	Past Experience	The Respondent must submit particulars of quantity of the past supplies of drugs made as per Annexure 3. Note: At least 80% quantity for similar drug as specified in the Schedule of	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-3)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		Requirements i.e. Appendix A' must have been supplied for any of the last 3 (three) financial years preceding the Bid Due Date, i.e., 2023-24, 2024- 25 & 2025-26. The Respondent shall submit the work done with satisfaction from the concerned authority. For the Purpose of quantification of 80% similar work only the Purchase order from Govt./Semi-Govt.& Hospitals registered under Maharashtra Public Trust Act 1950 shall be considered. Purchase Order from private hospitals shall not be considered.	
5	Average Annual Turnover	Average Annual Turnover (in last three financial years 2023-24, 2024- 25 & 2025-26. shall be as per mentioned in the Schedule of Requirements i.e. Appendix A.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6) along with audited financial statements confirming the average annual Turnover of the Bidder during the stated financial years must be submitted. The turnover should be as certified by the chartered accountant/statutory auditor (specifying UDIN) and having valid registration. Note: In case the annual accounts for the latest financial year are not audited and therefore the Bidder cannot make it available, the Bidder shall

Sr.No.	Basic Requirement	Specific Requirement	Documents required
			give an undertaking to this effect and the chartered accountant/statutory auditor shall certify the same. In such a case, the Bidder shall provide the audited financial statements for the financial year preceding the latest financial year for which the audited annual report is not being provided.
6	Net Worth	The net worth of the Bidder in the financial year immediately preceding the Bid Due date should be positive and should have not eroded by more than 30% (thirty percent) in the last three (3) years.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6). The Net Worth should be as certified by the chartered accountant/ statutory auditor (specifying UDIN) and having valid registration.
7	Production Capacity	Production capacity of the original drug manufacturer must be minimum Two (2) times of the quoted order quantity in last one financial year.	Certificate of Statutory Auditor/Chartered Accountant. As per Annexure 4.
8	Market Standing Certificate	Bidder should mandatorily possess 5 years Market Standing Certificate (i.e., for financial year (2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender as on Bid Due Date. The period of Market Standing will be reckoned from the date of issue of product/drug permission.	Market Standing Certificate as issued by Central or State Licensing Authority under the Applicable Law. Bill of landing of a foreign manufacturer and bill of entry of the importer, mentioning the country of

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing as applicable.	origin. Notarized/ certified copy of Drug Controller General of India, new Delhi, for permission for Items coming under, “New Drug and Fixed Dose Combinations” in form 45/46 as per Drugs & Cosmetic Act and Rules. Relevant period Market standing certificate for new drug/drugs out of patent period issued by licensing authority.
9	Proof of distribution network	Bidders, if not having their registered office, manufacturing unit, or distribution facility within Maharashtra State, must have an established and operational distribution network in Maharashtra State at the time of EOI submission. In case there is no registered office or established operational distribution network the respondent/bidder shall give undertaking for establishment of both within three (3) months from the last date of submission of EOI.	Proof of distribution network— such as a valid drug selling/distribution license issued by the state’s licensing authority, along with details of authorized distributors (names, addresses, contact details) must be submitted as part of the bid documentation Annexure 4 (A) and Copy of License of Sale / Distribution issued by State’s Licensing Authority
10	Blacklisting or banned	On the Bid Due Date, the Bidder should not be blacklisted or debarred by any ministry/department /attached offices/sub-ordinate offices under Government of	Affidavit as per Annexure 8

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		India and any State government, Autonomous bodies (established by Central/State govt), any Central/State PSUs for unsatisfactory past performance, corrupt, fraudulent or any other Fraudulent and Corrupt business practices. The bidder, whose drug has been declared as misbranded, spurious or adulterated or any criminal case in respect of the above is pending in any court, as on Bid Due Date shall not be eligible to participate for that particular drug, in the bid. Similarly, a Bidder convicted by court of law shall not be eligible to participate in the bid.	
11	Non-Conviction Certificate	The Tenderer(s) quoting for this tender shall not have been convicted by any Court of Law in India/overseas in lieu of deficiency noticed in the any of the quoted Product(s) in the tender and tender should not be submitted for such products for which conviction was granted by any Court of Law for a period of Three years from date of such order(s).	Non-Conviction certificate Issued by licensing authority/State FDA.
12	Litigation	The Bidder should not be involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings that may have an impact of	Affidavit as per Annexure 9.

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		affecting or compromising the delivery of services as required under this contract.	
13	Conflict of Interest	On the date of submission of the Bid, the Bidder should not have any conflict-of-interest situation.	Undertaking by the authorized signatory as per Annexure 2
14	Quantity specified in EOI	The quantity mentioned in the EOI is indicative in nature. Detail requirement will be given in subsequent RFP.	-

Appendix A: Schedule of Requirements

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
1	5 - Fluorouracil Inj.250mg	Inj. 5 Fluorouracil 250 mg/5 mL, Vial of 5 ml	Injectable	1276	22453
2	Acetylcysteine 200mg/ml Inj	Acetylcysteine 200mg/ml Inj 2ml ampoule	Injectable	172125	2310606
3	Actinomycin D Inj. 0.5mg	Actinomycin D Inj. 0.5mg, 2 ml Vial/Ampoule	Injectable	1000	800
4	Acyclovir 250mg Injection Freeze dried powder vial for I.V. infusion	Acyclovir 250mg Injection Freeze dried powder vial for I.V. infusion	Injectable	12375	240778
5	Acyclovir 500mg Inj	Acyclovir 500mg Inj	Injectable	46688	1618749
6	Acyclovir Inj. 250mg	Inj. Acyclovir 250 mg contains Acyclovir 250mg/ml Vial	Injectable	13851	479245
7	Adenosine Inj 3mg/ml 2ml Amp	Adenosine Inj 3mg/ml 2ml Amp	Injectable	8258	457617
8	Alteplase powder for inj 50mg	Inj. Alteplase 50mg contains; Alteplase Powder for Injection 50 mg., Vial	Injectable	1000	15200000
9	Alteplase Powder for Injection 20 mg (Protect from light and moisture and store at room temperature <30°C). Use reconstituted solution within a hours)	Alteplase Powder for Injection 20 mg (Protect from light and moisture and store at room temperature <30°C). Use reconstituted solution within a hours)	Injectable	1000	12161016
10	Amikacin inj 100mg	Inj. Amikacine sulphate 100 mg - 2 ml	Injectable	478062	2398724
11	Amikacin inj 500mg	Inj. Amikacine sulphate 500 mg - 2 ml	Injectable	801090	10039901
12	Amikacin Sulphate 100 mg Inj 2ml vial	Amikacin Sulphate 100 mg Inj 2ml vial	Injectable	9225	61180
13	Amikacin Sulphate 500 mg Inj 2ml vial	Amikacin Sulphate 500 mg Inj 2ml vial	Injectable	303638	3805428
14	Amikacine sulphate 250mg Inj 2ml vial	Amikacine sulphate 250mg Inj 2ml vial	Injectable	4613	95829
15	Amino Acid 10% 500 ml Bot.	Amino Acid 10% Essential and Non Essential for Parenteral nutrition OR Equivalent 500 ml Bot.	Injectable	10463	2416838
16	Amino Acid 200 ml- IV	Intravenous 10% Amino Acids Solution -Paediatric specific Intravenous 10% Amino Acids Solution with taurine, special	Injectable	33210	15276600

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		conditionally essential amino acid. - 100 ml			
17	Amino Acid 5% 100ml Bottle	Amino Acid 5% 100ml Bottle	Injectable	1000	84000
18	Amino Acid 5% 200ml Bottle	Amino Acid 5% 200ml Bottle	Injectable	1000	176000
19	Amino Acid 5% 250 ml. Bot.	Amino Acid 5% 250 ml. Bot.	Injectable	1000	174400
20	Amino Acid 5% 500ml Bot.	Amino Acid 5% (All 2 & Non 2)+ Sorbitol 5% OR Equivalent 500ml Bot.	Injectable	1508	417879
21	Amino Acids Intravenous 10% 100 ml	Amino Acids Intravenous 10% Solution -Paediatric specific Intravenous 10% Amino Acids Solution with taurine, special conditionally 2 amino acid. - 100 ml	Injectable	1519	459270
22	Aminophylline 250mg Inj 10ml vial	Aminophylline 250mg Inj 10ml vial	Injectable	11183	62801
23	Aminophylline Inj 25mg/ml	Inj. Aminophyllin - 25 mg per ml i.e. Each vial contains Aminophyllin 250 mg/10 ml, w/v	Injectable	159030	1211172
24	Amiodarone 50 mg/ml Inj 3ml Amp	Amiodarone 50 mg/ml Inj 3ml Amp	Injectable	18774	432703
25	Amoxicillin Inj. 500 mg	Inj. Amoxycillin 500 mg contains; Powder Amoxycillin Tryhydrate 500 mg in Each Vial	Injectable	1000	9040
26	Amoxycillin + Clavulanic acid inj. 600mg ie. 500mg + 100mg)	Inj. Amoxycillin + Clavunnic acid 600 mg Inj. Amoxycillin Sodium 500mg + Clavulanic acid as Potasium Salt 100 mg i.e. 600 mg (0.6 gm) in Vial	Injectable	4457403	78450293
27	Amoxycillin + Clavunnic acid 1.2gm Amoxycillin Sodium 1000 mg + Clavulanic acid as Potasium Salt 200 mg i.e. 1.2 gm (1.2 gm) in Vial	Amoxycillin + Clavunnic acid 1.2gm Amoxycillin Sodium 1000 mg + Clavulanic acid as Potasium Salt 200 mg i.e. 1.2 gm (1.2 gm) in Vial	Injectable	2725326	63879897
28	Amoxycillin Sodium 1gm + Clavulanic Acid 200mg per vial Inj	Amoxycillin Sodium 1gm + Clavulanic Acid 200mg per vial Inj	Injectable	554625	13000055
29	Amoxycillin Sodium 500mg + Clavulanic Acid 100mg per vial Inj	Amoxycillin Sodium 500mg + Clavulanic Acid 100mg per vial Inj	Injectable	1125	17955
30	Amphotericin B- 50 mg Injection (Liposomal)	Inj. Amphotericin B 50 mg Liposomal Each Ampoule contains Amphotericin B 50 mg (Liposomal)	Injectable	2579	6454295

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
31	Amphotericin B 50 mg/10 ml Vial Inj Plain	Amphotericin B 50 mg/10 ml Vial Inj Plain	Injectable	2475	220315
32	Amphotericin B 50mg /10 ml Emulsion Inj	Amphotericin B 50mg /10 ml Emulsion Inj	Injectable	1000	1292680
33	Amphotericin B 50mg/10 ml Lyophilized Plain Inj	Amphotericin B 50mg/10 ml Lyophilized Plain Inj	Injectable	1000	2267136
34	Ampicillin inj. 500 mg	Inj. Ampicillin 500 mg., Each Vial contains Ampicillin 500 mg.	Injectable	331407	3201392
35	Anti gas gangrene serum(AGGS) 25000 I.U. Inj	Anti gas gangrene serum(AGGS) 25000 I.U. Inj	Injectable	1000	12532696
36	Anti Rabies Monoclonal Antibody Docaravimab & Miromavimab Inj 1500IU/2.5ml	Anti Rabies Monoclonal Antibody- Docaravimab & Miromavimab Inj 1500IU/2.5ml	Injectable	1148	2019600
37	Anti Rabies Vaccine ID / IM (for Both ID/IM Use)	Anti Rabies vaccine Tissue culture 2.5 I U per Vial or amp or Purified vero cell Rabies vaccine 2.5 IU per Vial or amp or purified chick embryo vaccine 2.5 I U per Vial or amp & Sterile water for injection as diluents, Label should indicate for ID / IM use, Ampoule/Vial of 1 ml or 0.5ml	Injectable	15342696	2258444851
38	Anti-D Immunoglobulin Inj Monoclonal /Polyclonal 300 mcg	Anti D (Rho-D) immunoglobulin (Human) Polyclonal / Monoclonal - 300mcg in pfs/ single dose Vial	Injectable	25299	38758068
39	Anti-Rabies Immunoglobulin 300 IU	Human derived anti-rabies immunoglobulin 150 I U per ml - i.e. 300 IU per 2 ml PFS	Injectable	492480	232450560
40	Antiscorpion Venum Serum Inj. 10ml	Antiscorpion Venum Serum Inj 10ml vial	Injectable	1193	601402
41	Antisnake Venom Serum sterile powder with sterile water, lyophilized sterile solution 10ml	Inj. ASVS (Antivenom Lyophilised Polyvalent Antisnake Venom Serum Inj. (Polyvalent Inj.) enzyme refined 10 ml	Injectable	3411619	1351001025
42	Antitetanus Human Immunoglobulin Inj. 250 IU	Each Vial contains Human Tetanus Immunoglobulin Equivalent to Tetanus antitoxin 250 I. U. STabilizer: Glycine . 0.3 M Preservative: Thiomersal 0.01% w/v - 1 ml	Injectable	445500	1279476000
43	Antitetanus Human Immunoglobulin Inj. 500 IU	Each Vial contains Human Tetanus Immunoglobulin Equivalent to Tetanus antitoxin 500 I.	Injectable	5022	6424142

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		U. STabilizer: Glycine . 0.3 M Preservative: Thiomersal 0.01% w/v - 1 ml			
44	Arsenic Trioxide Injection 1mg/ml	Arsenic Trioxide Injection 1mg/ml contains; Arsenic Trioxide Injection 10mg/10ml, Single Dose Vial	Injectable	1000	160000
45	Artesunate 60 mg/ml Inj Combipack	Artesunate 60 mg/ml Inj This pack also contains 1ml ampl of sodium bicarbonate, and 5ml ampl of sodium chloride Combipack	Injectable	258750	2939814
46	Ascorbic Acid 500mg/5ml 5ml Amp Inj	Ascorbic Acid 500mg/5ml 5ml Amp Inj	Injectable	10125	64865
47	Atracurium besylate 10mg/ml Inj 2.5ml Amp	Atracurium besylate 10mg/ml Inj 2.5ml Amp	Injectable	146007	3655081
48	Atropin I V 100ml bottle Inj	Atropin I V 100ml bottle Inj	Injectable	5963	95400
49	Atropine Inj 0.6mg/ml	Inj. Atropine Sulphate 0.6 mg/ml - 1 ml amp	Injectable	764397	2427725
50	Atropine Inj 1mg/ml	Inj. Atropine Sulphate 1mg/ml - 1 ml amp	Injectable	1236870	989496
51	Atropine Inj infusion 30mg/50ml 50ml vial	Atropine Inj infusion 30mg/50ml 50ml vial	Injectable	2475	75240
52	Atropine Sulphate 0.6 mg/ml Inj 1ml Amp	Atropine Sulphate 0.6 mg/ml Inj 1ml Amp	Injectable	226823	460903
53	Atropine Sulphate 0.6mg/ml Inj 10ml vial	Atropine Sulphate 0.6mg/ml Inj 10ml vial	Injectable	78300	132170
54	Azithromycin 500mg 100mg/ml Inj 5ml vial	Azithromycin 500mg 100mg/ml Inj 5ml vial	Injectable	1519	167184
55	B Complex Injection 10ml	Each ml contains: Thiamine Hydrochloride 100 mg, Riboflavin 5' Phosphate Sodium 2 mg, Pyridoxine Hydrochloride 2 mg, Dexpanthenol 2 mg, Niacinamide 100 mg, with Benzyl Alcohol 2% as preservative, in Water for Injection. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH, 10 ml Vial	Injectable	1953720	27352080
56	Benzathine Penicillin G 12,00,000 I.U./vial Inj	Benzathine Penicillin G 12,00,000 I.U./vial Inj	Injectable	4275	44973
57	Benzathine Penicillin G 6,00,000 I.U./Vial Inj	Benzathine Penicillin G 6,00,000 I.U./Vial Inj	Injectable	1000	6896
58	Benzathine Penicillin Inj. 12Lac IU / Vial	Inj. Benzathine Penicillin 12 lac IU / Vial	Injectable	295731	2602433

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
59	Benzyl Penicillin (Crystalline) Inj (10 lakh)	Inj. Benzyl Penicillin 10 lac IU Inj. Benzyl Penicillin sterile powder 1000000IU/ Vial	Injectable	108891	541842
60	Benzyl Penicillin G Sterile powder for Inj 10,00,000 I.U./Vial	Benzyl Penicillin G Sterile powder for Inj 10,00,000 I.U./Vial	Injectable	4500	27108
61	Betamethasone 4mg/ml Inj 1ml ampl	Betamethasone 4mg/ml Inj 1ml ampl	Injectable	1125	3681
62	Betamethasone Inj 12mg	Inj Betamethasone 12mg/ml, 1 ml Ampoule	Injectable	1000	3200
63	Betamethasone Inj 4mg/ml	Inj Betamethasone 4mg/ml, 1 ml Ampoule	Injectable	270891	834344
64	Bleomycin Inj. 15 mg/iu	Inj. Bleomycin 15 mg/iu per Vial	Injectable	1000	168000
65	Bupivacaine 0.25% Injection	Inj. Bupivacaine HCL USP 0.25 %, 2.5mg/ml Vial	Injectable	37987	577399
66	Bupivacaine Heavy mixed with glucose solution Inj. 4ml	Inj Bupivacaine HCl(Anhydrous) 7.5mg + Dextrose 825mg(Anhydrous) per ML (4ml Ampoule)	Injectable	787590	10648217
67	Bupivacaine Hydrochloride (0.5%) 50mg/10ml	Inj Bupivacaine Hydrochloride (0.5%) 50mg/10ml, 20 ml Vial	Injectable	96255	1540080
68	Bupivacaine Hydrochloride (Heavy) 5 mg + Dextrose Monohydrate 80mg/ml Inj 4ml Amp	Bupivacaine Hydrochloride (Heavy) 5 mg + Dextrose Monohydrate 80mg/ml Inj 4ml Amp	Injectable	130815	1064311
69	Bupivacaine Hydrochloride 0.5% Inj 20ml vial	Bupivacaine Hydrochloride 0.5% 100mg/20ml Inj 20ml vial	Injectable	48544	873399
70	Bupivacaine Hydrochloride 50mg/10ml (5mg/ml) Inj 20ml vial	Bupivacaine Hydrochloride 50mg/10ml (5mg/ml) Inj 20ml vial	Injectable	2588	38485
71	Buprenorphine 0.3 mg/ml Inj 1ml amp	Buprenorphine 0.3 mg/ml Inj 1ml amp	Injectable	3600	33984
72	Buprenorphine 0.3 mg/ml Inj 2ml amp	Buprenorphine 0.3 mg/ml Inj 2ml amp	Injectable	4950	91080
73	Caffine Citrate 20mg Inj.	Caffine Citrate 20mg Inj. Contains; Caffine Citrate 20 mg/ ml (equivalent to 10 mg caffeine base/ ml). 3 ml Vial	Injectable	88830	5578524
74	Calcium Folate Inj. 3mg/ml	Calcium Folate Inj. 3mg/ml contains; Calcium Folate 3mg/ml, For Slow I.V./ I.M./I.V. use	Injectable	1000	58400
75	Calcium Gluconate 10 % w/v Inj 10 ml amp	Calcium Gluconate 10 % w/v Inj 10 ml amp	Injectable	129488	744812
76	Calcium Gluconate Inj. 100mg/ml	Inj. Calcium Gluconate 100 mg/ml(w/v) 10 ml	Injectable	644760	5054918

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
77	Calcium Gluconate Injection 1 gm. IV-10 ml amp	Calcium Gluconate Injection 1 gm. IV-10 ml amp	Injectable	25191	76581
78	Capreomycin Inj. 1000 mg.	Inj. Capreomycin 1000 mg. i.e. 1 gm Vial	Injectable	1000	160000
79	Capreomycin Inj.750 mg.	Inj. Capreomycin 750 mg. Vial	Injectable	1000	95200
80	Carbetocin Inj 100mcg/ml	Carbetocin Inj 100mcg/ml (Heat Stable at Room Temperature)	Injectable	2475	95040
81	Carboplatin 10 mg	Inj Carboplatin 10 mg/ml	Injectable	1000	640000
82	Carboprost 250mcg Inj 1ml Amp	Carboprost 250mcg Inj 1ml Amp	Injectable	10463	398412
83	Cefatoxime 500 mg Inj.	Cefatoxime 500 mg Inj.	Injectable	11250	87030
84	Cefazolin Powder for Injection 1gm	Cefazolin injection 1000 mg contains; Cefazolin Sodium Injection 1000 mg i.e. 1gm Vial	Injectable	270891	4550969
85	Cefazolin Powder for Injection 500mg	Cefazolin injection 500 mg contains; Cefazolin Sodium Injection 500 mg i.e 0.5gm Vial	Injectable	270891	2947294
86	Cefoperazone 1gm + Sulbactam 0.5gm Injection	Cefoperazone 1gm + Sulbactam 0.5gm Injection	Injectable	52184	2087370
87	Cefoperazone 500mg + sulbactam 500mg Inj	Cefoperazone 500mg + sulbactam 500mg Inj	Injectable	18563	279477
88	Cefoperazone and Sulbactam for Inj. 2gm	Cefoperazone 1gm + sulbactam 1gm Inj	Injectable	127125	3986640
89	Cefotaxime Inj. 1000mg	Cefotaxime Sodium 1gm Inj	Injectable	8790075	110543983
90	Cefotaxime Inj. 250mg	Inj. Cefotaxime 250 mg nj. Cefotaxime Sodium sterile powder 250 mg/Vial	Injectable	369225	2540268
91	Cefotaxime Sodium 500mg Inj	Cefotaxime Sodium 500mg Inj	Injectable	7577550	61190232
92	Ceftazidime + Avibactam 2.5g Injection	Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam	Injectable	1000	2720000
93	Ceftazidime Inj 500mg	Ceftazidime Inj 500mg	Injectable	1000	16000
94	Ceftazidime Inj. 1000mg	Ceftazidime Inj 1000 mg Contains Ceftazidime Powder for Inj, 1000 mg i.e. 1 gm Vial	Injectable	96179	3409335
95	Ceftazidime Inj. 250 mg	Ceftazidime Inj 250 mg Contains Ceftazidime Powder for Inj, 250 mg Vial	Injectable	3141	40330

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
96	Ceftriaxone Inj. 1000mg	Ceftriaxone Inj 1000 mg Contains Ceftriaxone Powder for Inj, 1000 mg i.e. 1gm Vial	Injectable	8838014	102351267
97	Ceftriaxone Inj. 250mg	Ceftriaxone Inj 250 mg Contains Ceftriaxone Powder for Inj, 250 mg Vial	Injectable	381375	2471310
98	Ceftriaxone Inj. 500mg	Ceftriaxone Inj 500 mg Contains Ceftriaxone Powder for Inj, 500 mg Vial	Injectable	5135130	41409688
99	Cefuroxime Injection 1000 mg	Cefuroxim Injection 1000mg contains; Cefuroxim Sodium Injection IP 1 gm along with Solvent 20 ml	Injectable	334136	10157742
100	Cefuroxime Injection 750 mg	Cefuroxime 750 mg Inj	Injectable	1000	23200
101	Chlorambucil Inj. 500mg	Chlorambucil Inj. 500mg	Injectable	1000	128000
102	Cholecalciferol Injection 600000 IU	Cholecalciferol Injection 600000 IU	Injectable	203780	2070407
103	Ciprofloxacin I V 100 ml Bottle	Ciprofloxacin 2mg/ml 100 ml Bottle I V	Injectable	3425085	25825141
104	Clarithromycin 500mg Inj	Clarithromycin 500mg Inj	Injectable	1125	252000
105	Clindamycin 150mg/ml Inj 4ml Vial	Clindamycin 600mg/4ml (150mg/ml) Inj 4ml Vial	Injectable	10238	377150
106	Clindamycin Phosphate 300mg/2ml Inj 2ml ampoule	Clindamycin Phosphate 300mg/2ml Inj 2ml ampoule	Injectable	55800	803520
107	Clonidine 150 mcg/ml 1ml amp Inj	Clonidine Hydrochloride 150 mcg/ml 1ml ampoule Inj	Injectable	4500	162000
108	Cloxacillin Injection 250 mg/Vial	Cloxacillin IP Inj 250 mg.	Injectable	4232	17606
109	Cloxacillin Injection 500 mg/Vial	Cloxacillin IP Inj 500 mg.	Injectable	1000	12000
110	Colistimethate Sodium Inj. 2 million I.U.	Colistimethate Sodium Inj.2 million I.U.	Injectable	5288	10575000
111	Colistomithate 1 MIU Inj	Colistimethate sodium 1 million iu Inj	Injectable	54225	3099761
112	Colistomithate 3 MIU Inj	Colistimethate sodium 3 million iu Inj	Injectable	6750	1297296
113	Concentrated Ringer Lactate 10 ml	Concentrated Ringer Lactate 10 ml	Injectable	101318	243162
114	Cyanocobalamin Inj 10000 mcg/10ml multi dose vial	Cyanocobalamin (Vitamine B 12) 1000mcg/mL solution for IM or SC contains benzyl alcohol Inj 10ml multi dose vial	Injectable	3488	58869

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
115	Cyclophosphamide Inj. 500mg	Inj. Cyclophosphamide 500 mg	Injectable	7088	419580
116	Cyclosporine Injection 100mg/ml	Cyclosporine Injection 100mg/ml	Injectable	7772	1709730
117	Dalteparine Sodium 2500 iu Anti factor Inj 0.2ml PFS	Dalteparine Sodium 2500iu Anti factor Inj 0.2ml PFS	Injectable	1350	179150
118	Dalteparine Sodium 5000 iu Anti factor Inj 0.2ml PFS	Dalteparine Sodium 5000 iu Anti factor Inj 0.2ml PFS	Injectable	1800	393466
119	Deferoxamine 500mg Inj	Deferoxamine 500mg Inj	Injectable	1913	205179
120	Deferoxamine mesylate Inj. 500mg	Deferoxamine mesylate Inj. 500mg	Injectable	6152	1461596
121	Desferrioxamine Injection 500 mg	Desferrioxamine Injection 500 mg contains; Powder for injection Desferrioxamine 500 mg Vial	Injectable	1000	159200
122	Dexamethasone 4mg/ml Inj	Dexamethasone 4mg/ml 1ml ampl Inj	Injectable	91125	260982
123	Dexamethasone Inj. 4mg/ml	Inj. Dexamethasone Sodium Phosphate 4 mg/ml - 2 ml Vial IM/IV -	Injectable	8432100	21154452
124	Dexamethasone Sodium Phosphate 4mg/ml Inj 2ml amp	Dexamethasone Sodium Phosphate 4mg/ml Inj 2ml amp	Injectable	473738	1356784
125	Dexmedetomidine 100mcg /ml Inj 2 amp	Dexmedetomidine hydrochloride 100mcg/ml Inj 2ml amp	Injectable	7673	1031184
126	Dexmedetomidine 100mcg/ml Inj 1ml amp	Dexmedetomidine hydrochloride 100mcg/ml Inj 1ml amp	Injectable	28283	1216374
127	Dextrose 5% I V 100 ml Bottle	Dextrose 5% w/v I. P.100 ml Bottle I V	Injectable	1000	8000
128	Dextrose 5% with Sodium Chloride 0.9 % W/V I.P. (DNS) I V 500 ml Bottle	Dextrose 5% with Sodium Chloride 0.9 % W/V I.P. (DNS) 500 ml Bottle I V	Injectable	951390	13545358
129	Dextrose 5% with Sodium Chloride 0.9%W/V I.P. (DNS) I V 100 ml Bottle	Dextrose 5% with Sodium Chloride 0.9%W/V I.P. (DNS) 100 ml Bottle I V	Injectable	1000	8000
130	Dextrose Inj I.V 10%	I. V. . Dextrose Anhydrous 10%, water for inj. qs. 500 ml - AFFS/BFS/FFS Technology	Injectable	244620	4575372
131	Dextrose Inj I.V 10%	Dextrose 10% w/v I. P.500 ml Bottle I V	Injectable	40500	648000
132	Dextrose Inj I.V 25%	Dextrose 25% w/v I. P.100 ml Bottle I V	Injectable	1201590	17432668

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
133	Dextrose Inj I.V 5%	Dextrose 5% w/v I. P. 500 ml Bottle I V	Injectable	1860750	25715565
134	Dextrose with Normal Saline Inj I.V 500ml	I. V. Dextrose 5% in Normal saline 0.9% (I. E. Glucose with sodium chloride 5% glucose, 0.9% sodium chloride (equivalent to 150 mmol/L Na ⁺ and 150 mmol/L Cl ⁻); 5% glucose, 0.45% sodium chloride (equivalent to 75 mmol/L Na ⁺ and 75 mmol/L Cl ⁻ w/v)AFFS/BFS/FFS Technology	Injectable	9965700	146535653
135	Diazepam Inj. 5mg/ml	Inj. Diazepam 5 mg/ml - 2 ml	Injectable	221056	745400
136	Diclofenac 25mg/ml Inj 3ml amp	Diclofenac 25mg/ml Inj 3ml amp	Injectable	231750	420858
137	Diclofenac Diethyl Amine Topical Solution	Each 30ml bottle contain: Diclofenac Diethyl Amine BP-2.32% w/v Equivalent to Diclofenac Sodium IP 2% w/v, Methyl Salicylate IP 10% w/v, Menthol IP 5.0% w/v Absolute Alcohol IP 10% v/v, In topical Solution Base (Non Aqueous) QS	Injectable	2250	330984
138	Diclofenac Sodium 25mg/ml Inj.	Inj. Diclofenac sodium 25 mg/ml - 3 ml Amp	Injectable	17362350	28196456
139	Diclofenac Sodium 75mg/ml 1ml Amp IV Bolus with Transcutol-P Free and Surfactant Free Injection	Inj Diclofenac Sodium 75mg/ml 1ml Ampoule IV Bolus with Transcutol-P Free and Surfactant Free	Injectable	542250	7808400
140	Dicyclomine 10mg/ml Inj 2ml amp	Dicyclomine 10mg/ml Inj 2ml amp	Injectable	25425	43324
141	Dicyclomine Hydrochloride Inj. 10mg/ml	Dicyclomine Hydrochloride Inj. 10mg/ml	Injectable	3745980	37459800
142	Digoxin 0.25mg/ml Inj 2ml amp	Digoxin 0.25mg/ml Inj 2ml amp	Injectable	1013	4212
143	Diltiazem HCL 5mg/mL Inj 5ml	Diltiazem HCl 5mg/mL Inj 5ml	Injectable	4388	49280
144	Diltiazem Inj 5mg/ml	Diltiazem Inj 5mg/ml	Injectable	23164	168632
145	Diphtheria Anti toxin (ADS) 10,000 I.U. Inj 10ml Amp/vial	Diphtheria Anti toxin (ADS) 10,000 I.U. Inj 10ml Amp/vial	Injectable	1000	1122744
146	Diphtheria Antitoxin Inj	Human Normal immunoglobulin inj for diphtheria OR Diphtheria antitoxin 10,000 i.u.- 5 ml	Injectable	3812	4279339
147	Dobutamine HCL 250mg/5ml Inj	Dobutamine HCl 250mg/5ml Inj	Injectable	61560	910103

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
148	Dobutamine Inj. 50mg/ml	Dobutamine Inj. 50mg/ml	Injectable	9315	187790
149	Docetaxel Inj. 20mg	Docetaxel Inj. 20mg	Injectable	1328	201780
150	Dopamine HCL 40mg/ml Inj 5ml amp	Dopamine HCL 40mg/ml Inj 5ml amp	Injectable	57713	460777
151	Dopamine Inj. 200mg/5ml	Inj. Dopamine HCL 200 mg/5 ml Vial (40 mg/ml)	Injectable	13473	113173
152	Dopamine Injection 40 mg/ml	Dopamine Injection 40 mg/ml Vial	Injectable	327348	2749723
153	Doxycycline Injection 100mg vial Combipack	Doxycycline Hydrochloride 100 mg injection with Ascorbic Acid 2 ml Amp (Combipack)	Injectable	13500	3240000
154	Drotaverine HCL 40mg/2ml Inj	Drotaverine HCL 40mg/2ml Inj	Injectable	71325	312689
155	Drotaverine Tablet 500mg	Inj. Drotaverine 40mg, 2ml Each 2ml contains Drotaverine HCL IP 40mg, Absolute Alcohol IP 8.0% w/v, Water for Injection q.s.	Injectable	557820	5355072
156	Emicizumab Inj 30mg	Each vial contains Inj Emicizumab 30mg	Injectable	1000	36516000
157	Ephedrine Injection 30mg/1ml	Ephedrine Injection 30mg/1ml 1ml ampoule	Injectable	1000	25088
158	Erythropoietin Injection 2000 IU	Erythropoietin Injection 2000 IU	Injectable	116910	8589612
159	Erythropoietin Injection 4000 IU	Erythropoietin Injection 4000 IU	Injectable	386910	31200422
160	Erythropoietin 4000IU/1.0ml Inj PFS	Erythropoietin 4000IU Vial/1.0ml Inj PFS	Injectable	16538	1733659
161	Erythropoietin 10000I.U./1.0ml Inj P.F.S.	Erythropoietin 10000I.U./1.0ml Inj P.F.S.	Injectable	6075	1735798
162	Erythropoietin 20000 I.U. Inj P.F.S.	Erythropoietin 20000 I.U. Inj P.F.S.	Injectable	1000	1095120
163	Erythropoietin 2000I.U./1.0ml Inj P.F.S.	Erythropoietin 2000I.U./1.0ml Inj P.F.S.	Injectable	7425	745114
164	Esmolol 100mg/10ml (10mg/ml) vial Inj	Esmolol 100mg/10ml (10mg/ml) vial Inj	Injectable	1800	207360
165	Esmolol Injection 10 mg/ml	Esmolol Injection 10 mg/ml Ampoule	Injectable	1000	36000
166	Ethamsylate 125mg/ml Inj 1ml amp	Ethamsylate 125mg/ml Inj 1ml amp	Injectable	20250	249480
167	Ethamsylate 125mg/ml Inj 2ml amp	Ethamsylate 125mg/ml Inj 2ml amp	Injectable	90450	353840

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
168	Etomidate 20mg/10ml Inj 10ml amp	Etomidate 20mg/10ml Inj 10ml amp	Injectable	4838	1662359
169	Etophylline 110mg + Theophylline 27mg/ml Inj 2ml amp	Etophylline 110mg + Theophylline 27mg/ml Inj 2ml amp	Injectable	59738	228436
170	Etophyllin B plus(A), Anhydrous Theophylline IP(B) combination inj. 84.7mg/ml(A)+25.3mg/ml	Etophyllin B plus(A), Anhydrous Theophylline IP(B) combination inj. 84.7mg/ml(A)+25.3mg/ml	Injectable	98010	156816
171	Etophylline 169.4mg + Theophyllin 50.6mg Inj 2ml amp	Etophylline 169.4mg + Theophyllin 50.6mg Inj 2ml amp	Injectable	78323	123436
172	Fat Emulsion I.V. 20% 100 ml Bot.	Fat Emulsion I.V. 20% w/v I.V. fat emulsion for Parenteral nutrition Soyabean oil ? 20 gm USP Egg Phospholipid/Lecithin ?1.2gm IP Glycerol unhydrous- 2.25gm IP Water fluid OR Equivalent 100 ml Bot.	Injectable	2475	792000
173	Fat Emulsion I.V. 20% 1500 ml Bag.	Fat Emulsion I.V. 20% -250ml & Amino Acid 5% + Sorbitol -750ml All in one pack . Only for T.P.N OR Equivalent 1500 ml Bag.	Injectable	1000	1329600
174	Fat Emulsion I.V. 20% 250 ml Bot.	Fat Emulsion I.V. 20% w/v I.V. fat emulsion for Parenteral nutrition Soyabean oil ? 20 gm USP Egg Phospholipid/Lecithin ?1.2gm IP Glycerol unhydrous- 2.25gm IP Water fluid ? 9 ? 250 ml / OR Equivalent 250 ml Bot.	Injectable	3825	1365525
175	Fat Emulsion I.V.10% 50ml Bot	Fat Emulsion I.V.10% with High Percentage of Omega3 Fatty Acid OR Equivalent 50ml Bot	Injectable	1000	128000
176	Fentanyl 50mcg/ml Inj 2ml amp	Fentanyl 50mcg/ml Inj 2ml amp	Injectable	35573	402965
177	Fentanyl inj. 50mcg/ml	Inj. Fentanyl 50mcg/ml	Injectable	1000	12160
178	Ferric Carboxymaltose 500mg/10 ML	Ferric Carboxymaltose 500mg/10 ML Injection	Injectable	567000	62995968
179	Filgrastim Inj. 300mcg	Inj Filgrastim 300 mcg per Vial-PFS	Injectable	27000	3024000
180	Fluphenazine Deconate Inj. 25mg	Inj. Fluphenazine HCL Deconate 25 mg/ml - 1 ml Ampoule	Injectable	12933	519079
181	Folic Acid Inj. 1mg/ml	Folic Acid Inj. 1mg/ml, (5 mg)	Injectable	1000	21600
182	Frusemide 10mg/ml Inj 2ml amp	Frusemide 10mg/ml Inj 2ml amp	Injectable	1045125	3239888

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
183	Furosemide Inj. 10mg/ml	Furosemide Inj. 10mg/ml	Injectable	152091	471482
184	Gentamicin inj. 10 mg/ml	Inj. Gentamycin 10 mg/ml - 2 ml amp/Vial	Injectable	1493204	4575176
185	Gentamicin inj. 40 mg	Inj. Gentamycin 40 mg/ml - 2 ml amp/Vial	Injectable	1424655	5812592
186	Gentamicin inj. 80 mg	Inj. Gentamycin 80 mg/ml - 2 ml amp/Vial	Injectable	619920	4066675
187	Gentamycin Sulphate 40mg/ml Inj 2ml amp	Gentamycin Sulphate 40mg/ml Inj 2ml amp	Injectable	284850	770234
188	Glucose Injection 10%	Glucose Injection 10%	Injectable	1000	6960
189	Glucose Injection 25%	Glucose Injection 25%	Injectable	1000	7680
190	Glucose Injection 5%	Glucose Injection 5% [IPHS173]	Injectable	42271	600245
191	Glucose Injection 50%	Glucose Injection 50%	Injectable	1000	7200
192	Glyceryl Trinitrate Injection 125mg/5ml	Glyceryl Trinitrate Inj. 125mg/5ml, 5 ml Amp	Injectable	4455	74844
193	Glycopyrrolate 0.2mg/ml Inj 1ml amp	Glycopyrrolate 0.2mg/ml Inj 1ml amp	Injectable	307769	1649639
194	Haloperidol 5mg/ml Inj 1ml amp	Haloperidol 5mg/ml Inj 1ml amp	Injectable	60183	2142274
195	Heparin Low molecular weight 40mg/ 0.4ml Inj PFS	Heparin Low molecular weight 40mg/ 0.4ml Inj PFS	Injectable	31950	1932336
196	Heparin Low molecular wieght 60mg/0.6ml Inj PFS	Heparin Low molecular wieght 60mg/0.6ml Inj PFS	Injectable	106988	7369299
197	Heparin Sodium 1000 I.U./ml Inj 5ml vial	Heparin Sodium 1000 I.U./ml Inj 5ml vial	Injectable	14182	984384
198	Heparin Sodium Inj.5000 IU/ml	Heparin Sodium 5000 I.U./ml Inj 5ml Vial	Injectable	95850	5668186
199	Heparin Sodium Topical Solution 1000 IU/ml 5ml vial	Heparin Sodium Topical Solution 1000 IU/ml 5ml vial	Injectable	1000	94872
200	Hepatitis B Immunoglobulin 200 i. u.	Hepatitis B Immunoglobulin 200 i. u. IM Single Dose	Injectable	13824	44236800
201	Hepatitis B Vaccine 20mcg 1 ml vial	Hepatitis B Vaccine 20mcg 1 ml vial (rDNA)	Injectable	13849	886320
202	Human Albumin 20%, 100ml	Albumin (Human) 20% is supplied in 10 g in 50 mL infusion bottle O R 20 g in 100 mL infusion bottle	Injectable	1000	2759040

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
203	Human Albumin 5% Isotonic 250ml IV	Human Albumin 5% Isotonic 250ml IV	Injectable	1000	3920000
204	Human Chorionic Gonadotropin Inj 1000 IU	Human Chorionic Gonadotropin Inj 1000 IU	Injectable	1000	471200
205	Human Chorionic Gonadotropin Inj 5000 IU	Human Chorionic Gonadotropin Inj 5000 IU	Injectable	1000	324800
206	Human Immunoglobulin for Intravenous Administration 10ml Vial IV	Each ml Solution Contains Human Plasma Protein 50mg thereof Immunoglobulin & gt;95% IgM 6mg, IgA 6mg IgG 38mg	Injectable	1000	3737600
207	Human Insulin plain 40iu/ml soluble	Highly purified human neutral insulin 40iu/ml - 10 ml soluble	Injectable	75384	9073218
208	Hyaluronidase 1500 IU Powder for Solution for Injection 2ml vial	Hyaluronidase 1500 IU Powder for Solution for Injection 2ml vial	Injectable	7088	756832
209	Hydrocortisone Sodium Succinate Inj. 100mg	Inj. Hydrocortisone Sodium Succinate 100mg; Vial	Injectable	1444590	12134556
210	Hydrocortisone sodium succinate injection 200 mg	Inj. Hydrocortisone Sodium Succinate 200mg; Vial	Injectable	391311	23782317
211	Hydroxy Propyl Methyl Cellulose USP 2% in sterile isonic base PFS	Hydroxy Propyl Methyl Cellulose USP 2% in sterile isonic base PFS Inj 2ml PFS	Injectable	18675	1531201
212	Hydroxyethyl Starch (Hetastarch) Inj 6% 500ml	I.V. Hydroxyethyl starch 6% IPHydroxyethyl starch 130/ 04, 6% saline solution Plasma Volume Expander IV 1) 6% Hydroxy Ethyl Starch 2) Low mean molecular wt. From 1,00,000- 1,50,000 daltons 3) High dose flexibility up to 50mls/ kg. b.w./day 4) Minimal interference in coagulation mechanism, grouping cross matching. 5) Low risk of anaphylaxis 6) Bottle of 500ml.	Injectable	86994	44192952
213	Hydroxyethyl Starch I V (130/0.4) 500 ml . Bot.	Hydroxyethyl Starch (130/0.4)with Calcium 500 ml . Bot.	Injectable	3263	483894
214	Hydroxyethyl Starch I V (200/0.5) 6 % 500 ml Bot.	Hydroxyethyl Starch (200/0.5) 6 % 500 ml Bot.	Injectable	8888	1489118

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
215	Hyoscine Butyl Bromide Inj. 20mg/ml	Hyoscine Butyl Bromide 20mg/ml Inj 1ml amp	Injectable	524745	3993309
216	Hyoscine Butyl-Bromide Injection 20 mg/ml	Hyoscine Butyl-Bromide Injection 20 mg/ml	Injectable	21870	174960
217	Imipenem 250mg + Cillastatin 250mg Inj	Imipenem 250 mg + Cillastatin 250 mg Inj	Injectable	2250	193320
218	Imipenem 500mg + Cillastatin 500mg Inj	Imipenem 500mg + Cillastatin 500mg Inj	Injectable	3150	443999
219	Immunoglobulin Human Normal 5% for Intravenous use 0.5gm (IVIG) 10ml vial	Immunoglobulin Human Normal 5% for Intravenous use 0.5gm/10ml (IVIG) 10ml vial	Injectable	1000	880000
220	Immunoglobulin Human Normal 5% for Intravenous use 5gm (IVIG) 100ml vial	Human Normal Immunoglobulin 5% for Intravenous use 5gm (IVIG) 100ml vial	Injectable	5591	36220377
221	Inj Paclitaxel 100 Mg	Paclitaxel 100mg Inj,100mg/vial	Injectable	1000	292000
222	Inj. Artesunate 120 mg Vial	Inj. Artesunate 120 mg Vial contains; Artesunate with Normal Saline & Sodabicarb Powder for Dilution Inj. 120mg	Injectable	1000	13600
223	Inj. Artesunate 60 mg Vial	Inj. Artesunate 60 mg Vial contains; Artesunate with Normal Saline & Sodabicarb Powder for Dilution Inj. 60mg	Injectable	685530	7788718
224	Inj. Carboplatin 150 mg	Carboplatin 150mg Inj ,150mg/15ml Vial	Injectable	1000	304000
225	Inj. Carboplatin 450mg	Carboplatin 450mg Inj 450mg/45ml Vial	Injectable	1000	852000
226	Inj. Cyclophosphamide 500mg	Cyclophosphamide 500mg Inj	Injectable	1000	42880
227	Inj.Rituximab 500 mg	Rituximab 500mg Inj,500mg/50ml	Injectable	1000	5911200
228	Injection insulin rapid	Injection insulin rapid	Injectable	35359	12729150
229	Insulin Aspart 100iu 3ml pfs Inj	Insulin Aspart 100iu 3ml pfs Inj	Injectable	1000	1279760
230	Insulin Degludec 100 units/ml 3ml Inj PFP	Insulin Degludec 100 units/ml 3ml Inj PFP	Injectable	1575	1905120
231	Insulin Highly Purified Human Neutral Inj (Regular) 40 I.U./ml 10ml vial	Insulin Highly Purified Human Neutral Inj (Regular) 40 I.U./ml 10ml vial	Injectable	27833	1543408

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
232	Insulin Highly Purified Human Premixed 30% Regular + 70% NPH Inj 40IU/ml 10ml vial	Insulin Highly Purified Human Premixed 30% Regular + 70% NPH Inj 40IU/ml 10ml vial	Injectable	3926	247511
233	Insulin Lente Basal	Basal Insulin Analogue : Insulin 100 IU/ml, 3 ml PFS	Injectable	1782	805464
234	Insulin Mixtard	Insulin Mixtard Rapid Injection	Injectable	13824	1940668
235	Insulin Soluble Zinc (Human) 40 IU /ml 10 ml Vial	Insulin Soluble Zinc (Human) 40 IU /ml 10 ml Vial	Injectable	13163	1579500
236	Intra peritoneal Dialysis Fluid (I.P.) (1.7%) 1000 ml bottle	Intra peritoneal Dialysis Fluid (I.P.) (1.7%) Sterile, Non-Pyrogenic ,Single use container 1000 ml bottle	Injectable	1000	29080
237	Iron Sucrose 200 mg (20mg/ml), 10ml Ampoule	Inj. Iron Sucrose 200 mg (20mg/ml), 10ml Ampoule Each ml contains 20 mg elemental iron as iron sucrose in water for injection. (200 mg elemental iron per 10 mL),	Injectable	1075950	11189880
238	Iron Sucrose 20mg/ml 2.5ml amp Inj	Iron Sucrose 20mg/ml 2.5ml amp Inj	Injectable	13050	102897
239	Iron Sucrose 20mg/ml 5ml amp Inj	Iron Sucrose 20mg/ml 5ml amp Inj	Injectable	183488	2137262
240	Isoflurane USP/IP/BP Liquid for Inhalation 100ml Bottle Inj	Isoflurane USP/IP/BP Liquid for Inhalation 100ml Bottle Inj	Injectable	5333	2214054
241	Isolyte-P I V 500ml	I.V. Isolyte-P (: Each 100 mL of Isolyte P (Multi-Electrolyte Injection) in 5% Dextrose contains:Hydrous Dextrose USP 5 g; Sodium Acetate Trihydrate USP 0.32 gPotassium Chloride USP 0.13 g; Magnesium Chloride Hexahydrate USP 0.031 gDibasic Potassium Phosphate USP 0.026 g; Water for Injection USP qs pH adjusted)500ml	Injectable	18473	628065
242	Isoprenaline 2mg/1ml Inj	Isoprenaline 2mg/1ml Inj	Injectable	1000	33848
243	Isoxsuprine Hyudrochloride 5mg/ml Inj 2ml amp	Isoxsuprine Hyudrochloride 5mg/ml Inj 2ml amp	Injectable	1000	7992
244	Kanamycin Injection 1gm	Kanamycin Injection 1000 mg contains; Kanamycin Powder for Injection 1000mg/5ml, i.e. 1gm	Injectable	1000	24520
245	Kanamycin Injection 500 mg	Kanamycin Injection 500 mg contains; Kanamycin Powder for Injection 500mg/5ml	Injectable	1000	7752

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
246	Kanamycin Injection 750 mg	Kanamycin Injection 750 mg contains; Kanamycin Powder for Injection 750mg/5ml	Injectable	1000	23184
247	Ketamine Hydrochloride Inj. 10mg/ml	Inj. Ketamine HCL 10mg/ml, 20 ml Vial	Injectable	46575	18630000
248	Ketamine Hydrochloride Inj. 10mg/ml	Ketamine Hydrochloride Inj 10mg/ml 10ml Vial	Injectable	3893	294117
249	Ketamine Hydrochloride Inj. 50mg/ml	Ketamine Hydrochloride 50mg/ml Inj 10ml Vial	Injectable	69485	14920824
250	Labetalol 5mg/ml 4ml Amp	Labetalol 5mg/ml 4ml Amp	Injectable	41254	2831657
251	Labetalol Inj. 20mg	Inj. Labetalol HCL 20 mg	Injectable	104760	4190400
252	Labetalol Inj. 5mg/ml	Inj. Labetalol HCL 5 mg/ml	Injectable	291519	5363950
253	Leucovorin (Folinic Acid) 50mg Inj	Leucovorin (Folinic Acid) 50mg Inj, 50mg/5ml	Injectable	1000	23200
254	Levetiracetam 100mg/ml Inj 5ml Vial	Levetiracetam 100mg/ml Inj 5ml Vial	Injectable	261000	9187200
255	Levetiracetam 500mg Injection	Inj. Levetiracetam 500mg contains: Levetiracetam 500mg Sodium Chloride 45mg, pH – 5.5 with glacial acetic acid, 8.2 mg sodium acetate trihydrate with Water for Injection	Injectable	98280	10614240
256	Levofloxacin 5mg/ml (500mg) 100ml -IV	I. V, Levofloxacin 5 mg/mL (500 mg) (as hemihydrate), 100 mL flexible container, 100 mL fill (Inj. Levofloxacin 500 mg/100 ml) AFFS/BFS/FFS Technology	Injectable	22680	1814400
257	Levofloxacin I V 100ml bottle	Levofloxacin 5mg/ml 100ml bottle I V	Injectable	172913	2137199
258	Lignocaine + Dextrose 5% spinal Heavy Inj 2ml amp	Lignocaine + Dextrose 5% spinal Heavy Inj 2ml amp	Injectable	1125	14400
259	Lignocaine 1% OR Lidocaine OR Xylocaine HCL 0.01 30ml vial Inj	Lignocaine 1% OR Lidocaine OR Xylocaine HCL 0.01 30ml vial Inj	Injectable	1350	14505
260	Lignocaine 2% Inj 30ml vial	Lignocaine 2% Inj 30ml vial	Injectable	80775	691434
261	Lignocaine 2% with Adrenaline (1:80,000 I.U.) Without Sodium Meta-bi-sulphate and	Lignocaine 2% with Adrenaline (1:80,000 I.U.) Without Sodium Meta-bi-sulphate and Chlorbutol For Dental infiltration anaesthesia	Injectable	2700	52704

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
	Chlorbutol For Dental infiltration anaesthesia				
262	Lignocaine 2% with Adrenaline 1:10000 I.U. Inj 30ml Vial	Lignocaine 2% with Adrenaline 1:10000 I.U. Inj 30ml Vial	Injectable	28148	263461
263	Lignocaine 2% with Adrenaline 1:200000 I.U. Inj 30ml vial	Lignocaine 2% with Adrenaline 1:200000 I.U. Inj 30ml vial	Injectable	14625	291681
264	Lignocaine 4% topical 30ml vial	Lignocaine 4% topical 30ml vial	Injectable	74183	1053392
265	Lignocaine HCI 2% I.P Inj.	Lignocaine HCI 2% I.P Inj.	Injectable	667980	5326740
266	Lignocaine HCL 21.3mg + Sodium chloride 0.6mg for Cardiac use Inj 50 ml vial	Lignocaine HCL 21.3mg + Sodium chloride 0.6mg for Cardiac use Inj 50 ml vial	Injectable	1000	24000
267	Lignocaine Injection 5% w/v	Lignocaine Injection 5% w/v	Injectable	1000	42400
268	Lignocaine with Adrenaline Inj.	Lignocaine with Adrenaline Inj. (20mg + 5 mcg) per 30 ml	Injectable	188190	2423887
269	Lignocaine+Adrenalin inj 1%+1:200000 (5 mcg/ml)	Lignocaine+Adrenalin inj 1%+1:200000(5 mcg/ml)	Injectable	55782	473031
270	Lignocaine+Adrenalin inj 2%+1:200000 (5 mcg/ml)	Lignocaine+Adrenalin inj 2%+1:200000(5 mcg/ml)	Injectable	56862	591365
271	Linezolid I V 300ml Bottle	Linezolid 2mg/ml 300ml Bottle I V	Injectable	77468	3887009
272	Lorazepam 2mg/ml Inj 2ml Amp	Lorazepam 2mg/ml Inj 2ml Amp	Injectable	58725	455706
273	Lorazepam Injection 1 mg/ml	Lorazepam Injection 1 mg/ml	Injectable	1000	4160
274	Lorazepam injection 2 mg/ml	Lorazepam injection 2 mg/ml	Injectable	89100	555271
275	L-Ornithine L-aspartate Inj. 500 mg/ml 10 ml amp	L-Ornithine L-aspartate Inj. 500 mg/ml 10 ml amp	Injectable	1913	413100
276	Low molecular weight heparin 0.6 IU (Enoxaparin)	Low molecular weight heparin 0.6 IU (Enoxaparin) PFS	Injectable	8019	552349
277	Lung Surfactant 5ml	Inj. Lung Surfactant Contains Surfactant Bovine Lipid Extract 27mg/ml, 4 ml Vial	Injectable	1404	7862400
278	Magenesium sulphate Inj 50 % w/v - 2 ml	Magnesium Sulphate 50% w/v Inj 2ml amp	Injectable	213098	652931

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
279	Magnesium	Xylidyl Blue method linearity more than 8 mg/dl	Injectable	1000	1100000
280	Magnesium Sulphate 50% w/v	Inj. Magnesium Sulphate 50 % w/v - 2 ml i.e. Each ml contain 500 mg Magnesium Sulphate per ml, 2 ml Vial	Injectable	1461240	2775655
281	Magnesium Sulphate inj 500mg/ml	Inj. Magnesium sulphate 50 % w/v - 2 ml i.e. Each ml contain 500 mg magnesium sulphate per ml	Injectable	76491	145296
282	Mannitol I V 20% 100 ml Bottle	Mannitol 20% w/v I . P. 100 ml Bottle I V	Injectable	324338	4929930
283	Mannitol I V 20% 350 ml Bottle	Mannitol 20% w/v I . P. 350 ml Bottle I V	Injectable	13511	756630
284	Mannitol Inj.10%	I.V. Mannitol 10% 100 ml bottle AFFS Technology I.V. Mannitol 10% 100 ml (10 mg / ml) AFFS/BFS/FFS Technology	Injectable	368010	3532896
285	Mannitol Injection 20%	I.V. Mannitol 20% 100 ml bottle AFFS Technology I.V. Mannitol 20% 100 ml (20 mg / ml) AFFS/BFS/FFS Technology	Injectable	57591	875383
286	Medroxyprogesterone Acetate Injection 150 mg	Medroxyprogesterone Acetate Injection 150 mg	Injectable	1000	96000
287	Menadione Injection (Vitamin K3) 10mg/ml	Phytomenadion Injectable Solution 1mg/1 ml ampoule (Vitamin K)	Injectable	2811375	23390640
288	Meningococcal Group A, C, W-135 Vaccine	Meningococcal Group A oligosaccharide 10 micrograms to Carylnebacterium diphtheriae CRM 197 protein 16.7 to 33.3 micrograms Meningococcal group C oligosaccharide 5 micrograms conjugated to Carylnebacterium diphtheriae CRM 19 Meningococcal group W-135 oligosaccharide Vaccine	Injectable	1000	2456080
289	Mephenteramine Inj.15mg/ml	Mephenteramine Inj.15mg/ml Vial	Injectable	24138	1023451
290	Mephentermine 30mg/ml Inj 10ml vial	Mephentermine 30mg/ml Inj 10ml vial	Injectable	18090	1199584
291	Meropenem 1 gm + Sulbactam 1gm Inj	Meropenem 1 gm and Sulbactam 1gm Inj	Injectable	1800	2494800
292	Meropenem Inj. 1gm	Meropenam 1 gm Inj	Injectable	379575	22073045
293	Meropenem Inj. 500mg	Meropenam 500 mg Inj	Injectable	43650	1493878
294	Methadone Injection 10 mg/ml	Methadone Injection 10 mg/ml	Injectable	1000	32000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
295	Methotrexate inj 50mg/2ml	Methotrexate inj 50mg/2ml	Injectable	1000	17680
296	Methyl Ergometrine Maleate 0.2mg/ml Inj 1ml amp	Methyl Ergometrine Maleate 0.2mg/ml Inj 1ml amp	Injectable	366143	1526082
297	Methyl prednisolone acetate 40mg/ml Inj 1ml amp	Methyl prednisolone acetate 40mg/ml Inj 1ml amp	Injectable	11430	231800
298	Methyl Prednisolone Sodium succinate 125mg/vial Inj	Methyl Prednisolone Sodium succinate 125mg/vial Inj	Injectable	1000	41600
299	Methyl Prednisolone Sodium succinate 1gm/vial Inj	Methyl Prednisolone Sodium succinate 1gm/vial Inj	Injectable	13050	1974914
300	Methyl Prednisolone Sodium Succinate 40mg/ml Inj	Methyl Prednisolone Sodium Succinate 40mg/ml Inj	Injectable	4725	81270
301	Methyl Prednisolone Sodium succinate 500mg/vial Inj	Methyl Prednisolone Sodium succinate 500mg/vial Inj	Injectable	18068	1656573
302	Methylene Blue Solution for Injection Methylthioninium chloride trihydrate 10mg/mL Each mL of solution contains 10 mg of methylene blue 10ml amp	Methylene Blue Solution for Injection Methylthioninium chloride trihydrate 10mg/mL Each mL of solution contains 10 mg of methylene blue 10ml amp	Injectable	1913	306000
303	Methylrosanilinium Chloride (Gentian Violet) 100ml	Methylrosanilinium Chloride (Gentian Violet) 100ml	Injectable	54891	761448
304	Metoclopramide Hcl 5 mg/ml	Metoclopramide Hcl 5 mg/ml	Injectable	430002	698323
305	Metoclopramide Hydrochloride 5mg/ml Inj 2ml amp	Metoclopramide Hydrochloride 5mg/ml Inj 2ml amp	Injectable	34088	4065957
306	Metoclopramide Injection 5 mg/ml	Metoclopramide Injection 5 mg/ml	Injectable	19710	30353
307	Metoprolol 1mg/ml Inj 5ml amp	Metoprolol 1mg/ml Inj 5ml amp	Injectable	13838	189629
308	Metronidazole I V 100 ml Bottle	Metronidazole 5 mg/ ml 100 ml Bottle I V	Injectable	2483100	15752786
309	Metronidazole I.V Inj. 100ml	I V.Metronidazole - 5mg / ml I. V. Metronidazole 500 mg in 100 ml AFFS/BFS/FFS Technology	Injectable	5493420	42760781
310	Metronidazole Injection 5 mg/ml	Metronidazole Injection 5 mg/ml	Injectable	8910	63838
311	Midazolam 1mg/ml Inj 5ml vial	Midazolam 1mg/ml Inj 5ml vial	Injectable	26100	344729

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
312	Midazolam 5mg/ml Inj 1ml amp	Midazolam 5mg/ml Inj 1ml amp	Injectable	10710	156409
313	Midazolam Inj. 1mg/ml	Midazolam 1mg/ml Inj 10ml	Injectable	224757	3414508
314	Morphine inj 15mg/ml	Inj. Morphine sulphate 15 mg / ml	Injectable	1397	18008
315	Morphine Sulphate 10mg/ml	Inj. Morphine sulphate 10 mg / ml	Injectable	7711	141138
316	Multiple Electrolytes and Dextrose Injection Type 1 USP 500 ml Bot.	Multiple Electrolytes and Dextrose Injection Type 1 USP (Pediatric Maintenance solution with 5% Dextrose injection) 500 ml Bot.	Injectable	29700	482803
317	Multivitamin NFI Injection 10ml ampoule	Each ml contain: Vitamin B1 IP 10mg Vitamin B2 IP 2mg Vitamin B6 IP 2mg Niacinamide IP 100mg D-Panthenol IP 5mg 10ml amp	Injectable	1000	3053938
318	N-Acetylcysteine Inj 200mg/ml (5ml)	N- Acetylcysteine Inj 200mg/ml (5ml)	Injectable	1000	88880
319	Naloxone 0.4mg	Inj. Naloxone hcl 0.4mg i.e. 400mcg/ml - 1 ml	Injectable	1000	12000
320	Neostigmine Inj.	Inj. Neostigmine Each ml of the 1:2000 concentration contains Neostigmine Methylsulphate 0.5 mg/ml, Methylparaben 1.8 mg and Propylparaben 0.2 mg (used as preservatives), in Water for Injection q.s.pH (range 5.0 - 6.5) adjusted, when necessary, with Sodium Hydroxide - 1 ml USP	Injectable	371385	1895549
321	Neostigmine Methyl Sulphate 0.5 mg/ml Inj 1ml amp	Neostigmine Methyl Sulphate 0.5 mg/ml Inj 1ml amp	Injectable	102888	249401
322	Neostigmine Methyl Sulphate 0.5mg/ml Inj 5ml vial	Neostigmine Methyl Sulphate 0.5mg/ml Inj 5ml vial	Injectable	7875	75852
323	Nitroglycerine 5mg/ml Inj 5ml amp	Nitroglycerine 5mg/ml Inj 5ml amp	Injectable	38025	696010
324	Noradrenaline 2mg/ml Inj 2ml amp	Noradrenaline 2mg/ml Inj 2ml amp	Injectable	521663	3868649
325	Noradrenaline Injection 2 mg/ml	Inj. Noradrenaline 4 mg in 2 ml ie. 2 mg per ml	Injectable	80730	229919
326	Octreotide 100mcg/ml Inj 1ml amp	Octreotide 100mcg/ml Inj 1ml amp	Injectable	51188	5187137
327	Ofloxacin I V 100ml bottle	Ofloxacin 2 mg/ml 100ml bottle I V	Injectable	2700	25272
328	Olanzapine Injection 10 mg	Olanzapine Injection 10 mg/ml	Injectable	19073	610344

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
329	Ondansetron 2 mg Inj	Each ml to contain: Ondansetron 2 mg	Injectable	187875	724446
330	Ondansetron 4mg/ml Inj 2ml amp	Ondansetron 4mg/ml Inj 2ml amp	Injectable	447784	1074681
331	Ondansetron inj I.P 2mg/ml	Ondansetron 2mg/ml Inj 2ml amp	Injectable	7534665	14312247
332	Oxytocin 5 I.U./ml Inj 1ml amp	Oxytocin 5 I.U./ml Inj 1ml amp	Injectable	664425	2940905
333	Oxytocin Inj. 10 IU	Inj. Oxytocin Each ml. to contain: Synthetic Oxytocin 10 IU 1 ml. amp.	Injectable	611010	2761765
334	Oxytocin Inj. 5 IU	Inj. Oxytocin Each ml. to contain: Synthetic Oxytocin 5 IU 1 ml. amp.	Injectable	3802950	21448638
335	Paclitaxel 100mg Vial	Paclitaxel 100mg/16.7 ml Vial	Injectable	1643	525600
336	Paclitaxel 260mg Vial	Paclitaxel 260mg Inj	Injectable	1000	635200
337	Paclitaxel 30mg Inj	Paclitaxel 30mg Inj,30mg/5ml	Injectable	2678	371685
338	Palonosetron 0.25 mg/ 5 ml vial Injection	Injection Palonosetron 0.25 mg/ 5 ml vial	Injectable	1000	31360
339	Pantoprazole 40mg/10ml Inj 10ml vial	Pantoprazole 40mg/10ml Inj 10ml vial	Injectable	1868738	9268938
340	Pantoprazole Inj. 4mg/ml	Inj. Pantaprazole 4 mg/ ml , 10 ml Vial	Injectable	10520550	116146872
341	Papaverine 30mg/ml Inj 2ml amp	Papaverine 30mg/ml Inj 2ml amp	Injectable	1000	10760
342	Paracetamol 10mg/ml Inj 100ml bottle	Paracetamol 10mg/ml Inj 100ml bottle	Injectable	727538	18252461
343	Paracetamol 150mg/ml Inj (IV and IM both use) 2ml amp	Paracetamol 150mg/ml Inj (IV and IM both use) 2ml amp	Injectable	3009960	10414462
344	Paracetamol IV 1gm, 100ml	Inj. Paracetamol IV 1gm, 100ml	Injectable	1320030	21466856
345	Pediatric Solution like Isolyte P, N/2 & N/5	Pediatric Solution like Isolyte P, N/2 & N/5	Injectable	202284	3560198
346	Pentazocine Lactate 30mg/ml Inj 1ml amp	Pentazocine Lactate 30mg/ml Inj 1ml amp	Injectable	2087798	18790178
347	Pheniramine Maleate 22.75mg/ml Inj 10ml vial	Pheniramine Maleate 22.75mg/ml Inj 10ml vial	Injectable	18675	265932
348	Pheniramine Maleate Inj. 22.75 mg/ml	Pheniramine Maleate 22.75mg/ml Inj 2ml amp	Injectable	7109550	12797190

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
349	Phenobarbitone Sodium 200mg/ml Inj 1ml amp	Phenobarbitone Sodium 200mg/ml Inj 1ml amp	Injectable	13860	201469
350	Phenytoin Injection 25 mg/ml	Inj. Phenytoin Sodium 25 mg/ml - 2 ml (Diphenyl Hadantoin Sodium)	Injectable	1180440	5666112
351	Phenytoin Injection 50 mg/ml	Phenytoin Injection 50 mg/ml	Injectable	8910	54529
352	Phenytoin Sodium 50mg/ml (Diphenyl Hadantoin Sodium) Inj 2ml amp	Phenytoin Sodium 50mg/ml (Diphenyl Hadantoin Sodium) Inj 2ml amp	Injectable	284400	1271837
353	Phytomenadione (Vitamin K1) Inj 10 mg/ml (Protect from light)	Phytomenadione (Vitamin K1) Inj 10 mg/ml (Protect from light)	Injectable	2131466	8798690
354	Pilocarpine 0.5% Inj 1ml	Pilocarpine nitrate 0.5% w/v ophthalmic solution without preservative Inj 1ml	Injectable	5513	79380
355	Piperacilin 4gm + Tazobactam 0.5 mg Inj	Piperacilin 4gm + Tazobactam 0.5 mg Inj	Injectable	764006	34221334
356	Piperacillin + Tazobactam for Injection USP 1gm+125mg	Piperacillin + Tazobactam for Injection USP 1gm+125mg	Injectable	129060	2989030
357	Piperacillin + Tazobactam for Injection USP 2gm+250mg	Piperacillin + Tazobactam for Injection USP 2gm+250mg	Injectable	209520	8372419
358	Piperacillin + Tazobactam for Injection USP 4gm+500mg	Piperacillin + Tazobactam for Injection USP 4gm+500mg	Injectable	201555	17414352
359	Pneumoccal Polysaccharide vaccine 0.5ml Inj	23 Valent Pneumococcal Polysaccharide vaccine Each dose contains purified Polysaccharide of 23 stereotypes of Stepto. Pneumoniae 1,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14,15B,17F,18C,19A,19F,20,22F,23F,33F(SC/IM) and PCV 13 single dose 0.5ml vial	Injectable	1000	757216
360	Pneumococcal 13 valent Conjugate Vaccine	Pneumococcal 13-valent Conjugate Vaccine pre-filled syringe	Injectable	1000	2480000
361	Porcine lung Surfactant 1.5ml Injection	Each ml Contains 80mg of Lung Surfactant Poractant Alfa Suspension for Intratracheal Administration	Injectable	1000	7200000
362	Potassium Chloride 150mg/ml Inj 10ml amp	Potassium Chloride 150mg/ml Inj 10ml amp	Injectable	152753	973950

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
363	Potassium Chloride Injection 150 mg/ml	Potassium Chloride Injection 150 mg/ml	Injectable	70146	1442202
364	Pralidoxime Chloride 1gm Inj	Pralidoxime Chloride 1gm Inj	Injectable	89775	4963049
365	Pralidoxime Chloride 500 mg (PAM)	Inj. Pralidoxime Chloride 500 mg/ 20 ml (25 mg/ml)	Injectable	322155	11043473
366	Premix Insulin 30:70 Injection (Regular: NPH)	Premix Insulin 30:70 Injection (Regular: NPH)	Injectable	70470	3495312
367	Premix Insulin 30:70 Injection 40 IU/ml	Premix Insulin 30:70 Injection 40 IU/ml	Injectable	62910	3522960
368	Promethazine Hydrochloride 25mg/ml Inj 2ml amp	Promethazine Hydrochloride 25mg/ml Inj 2ml amp	Injectable	2903099	9173791
369	Propofol 1%	Injection Propofol 1% MCT/LCT in Fat emulsion with Oleic acid i.e. 10 mg/ml - 10 ml Vial	Injectable	80622	3792459
370	Propofol 1% I V 10 ml vial/amp	Propofol 1% MCT/LCT in Fat emulsion with oleic acid i.e. 10 mg/ml - 10 ml Vial Inj 10 ml vial/amp	Injectable	75150	1233662
371	Propofol 1% I V 20 ml vial/amp	Propofol 1% MCT/LCT in Fat emulsion with oleic acid i.e. 10 mg/ml - 20 ml Vial Inj 20 ml vial/amp	Injectable	6750	401976
372	Propofol 1% I V 50 ml vial/amp	Propofol 1% MCT/LCT in Fat emulsion with oleic acid i.e. 10 mg/ml - 50 ml Vial Inj 50 ml vial/amp	Injectable	1000	160000
373	Protamine Sulphate 50mg/5ml Inj 5ml amp	Protamine Sulphate 50mg/5ml Inj 5ml amp	Injectable	3929	325280
374	Quinine Dihydrochloride I.P. 300mg/ml Inj 2ml amp	Quinine Dihydrochloride I.P. 300mg/ml Inj 2ml amp	Injectable	55116	943145
375	Rabies Antiserum 1500 IU/5ml Inj IM & SC	Rabies Antiserum 1500IU/5ml Inj IM & SC	Injectable	206213	50753021
376	Rabies Human Monoclonal Antibody (r-DNA origin) 100 IU/2.5 ml	Recombinant Rabies Human Monoclonal Antibody (r-DNA origin) Injection 100 IU / 2.5 ml	Injectable	2430	1166400
377	Rabies Immunoglobulin 300 IU/2ml Inj 2ml Vial	Rabies Immunoglobulin 300 IU/2ml Inj 2ml Vial	Injectable	1000	2777600
378	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 Units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial	Injectable	160448	28842043

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
379	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial	Injectable	32850	5905116
380	Ranitidine 50mg/2ml Inj 2ml amp	Ranitidine 50mg/2ml Inj 2ml amp	Injectable	13500	25164
381	Ranitidine Inj. 25mg/ml	Inj. Ranitidine HCL 25 mg/ ml - 2 ml Ampoule Each 1 mL of aqueous solution contains ranitidine 25 mg (as the hydrochloride); phenol 5 mg as preservative; and 0.96 mg of monobasic potassium phosphate and 2.4 mg of dibasic sodium phosphate as buffers. 2 ml	Injectable	2649150	5828130
382	Remdesivir 100 mg Vial	Inj. Remdesivir 100 mg Vial (Lyophilized Powder)	Injectable	1000	1174400
383	Rifabutin 500 mg Injection	Rifabutin 500 mg Injection	Injectable	1000	27200
384	Ringers Lactate (compound solution) I V 500ml bottle	IV Compound Ringer Lactate IP each 100ml contains Sodium Lactate IP 0.32gm, Sodium chloride IP 0.6gm, Potassium chloride IP 0.04gm, Calcium chloride IP 0.027gm, Water for injection qs AFFS or BFS or FFS Technology 500 ml Bot	Injectable	10575675	164599806
385	Risperidone Inj. 25 mg	Risperidone Inj. 25 mg	Injectable	353511	452494080
386	Rituximab 100mg Inj	Rituximab 100mg Inj,100mg/10ml	Injectable	1000	1447200
387	Rocuronium 50mg/5ml Inj 5ml amp	Rocuronium 50mg/5ml Inj 5ml amp	Injectable	19080	2906266
388	Ropivacaine 0.75% 4ml amp Injection	Inj. Ropivacaine 0.75% (7.5mg/ml) 4ml amp.	Injectable	2475	207900
389	Semaglutide 0.25 mg (r-DNA) Inj	Semaglutide Inj. 0.25 mg (r-DNA)	Injectable	1000	8680000
390	Semaglutide 1 mg (r-DNA) Inj	Semaglutide Inj. 1 mg (r-DNA)	Injectable	1000	11080000
391	Semaglutide 2.4 mg (r-DNA) Inj	Semaglutide Inj.2.4 mg (r-DNA)	Injectable	1000	13120000
392	Sevoflurane Injection 1%(A)+1:200000 (5mcg/ml)(B)	Sevoflurane Injection 1%(A)+1:200000 (5mcg/ml)(B) [IPHS10]	Injectable	1000	960000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
393	Snake Venom Antiserum Injection a) Soluble/Liquid Polyvalent	Snake Venom Antiserum Injection a) Soluble/Liquid Polyvalent	Injectable	356400	85536000
394	Sodium Bicarbonate Inj. 7.5 mg/ml	Inj. Sodabarbonate 7.5 mg/ml (7.5%) - 10 ml Sodium Bicarbonate, nonpyrogenic solution of Sodium Bicarbonate, in Water for Injection, It contains no antimicrobial agent. Composition, osmolarity, pH and ionic (NaHCO ₃) (g/L) Osmolarity (mOsmol/L) (calc.) *pH Sodium Bicarbonate 10ml	Injectable	1118205	6948079
395	Sodium Chloride - Normal Saline 0.9% Inj. I.V. 100ml	I. V. Sodium Chloride (Normal Saline) 0.9% isotonic (equivalent to Na ⁺ 154 mmol/L, Cl ⁻ 154 mmol/L).w/v AFFS/BFS/FFS Technology	Injectable	270000	2808000
396	Sodium Chloride - Normal Saline 0.9% Inj. I.V. 500ml	I. V. Sodium Chloride (Normal Saline) 0.9% isotonic (equivalent to Na ⁺ 154 mmol/L, Cl ⁻ 154 mmol/L).w/v AFFS/BFS/FFS Technology	Injectable	8307900	152865360
397	Sodium Chloride 0.9% w/v with Potassium chloride 0.30% (20 mcg) I V 500 ml Bottle	Sodium Chloride 0.9% w/v with Potassium chloride 0.30% (20 mcg) 500 ml Bottle I V	Injectable	1125	25200
398	Sodium chloride I V 0.45% 500ml	Sodium chloride 0.45% w/v 500ml I V	Injectable	122625	1962000
399	Sodium Chloride I V 0.9% 100 ml Bottle	Sodium Chloride 0.9% w/v I.P.100 ml Bottle I V	Injectable	2659500	16637832
400	Sodium Chloride I V 0.9% 500 ml Bottle	Sodium Chloride 0.9% w/v I.P. 500 ml Bottle I V	Injectable	3080480	38641535
401	Sodium Nitropruside 25mg/ml Inj 2ml amp	Sodium Nitropruside 25mg/ml Inj 2ml amp	Injectable	1000	48000
402	Sodium Nitroprusside Inj.10mg/ml	Inj. Sodium Nitroprusside - Each 2 mL Vial contains the equivalent of 20 mg sodium nitroprusside dihydrate in sterile water for injection.	Injectable	76302	9766656
403	Sodium Valproate 100mg/ml Inj 5ml Vial	Sodium Valproate 100mg/ml Inj 5ml Vial	Injectable	10575	182736
404	Streptokinase Inj. 15Lac IU	Streptokinase 15 Lac I.U. Inj single dose	Injectable	7814	5345260
405	Streptokinase Inj. 7.5Lac IU	Streptokinase 7.5 Lac I.U. Inj single dose	Injectable	1386	975672
406	Streptomycin Inj 0.75 gm Vial	Streptomycin 0.75gm/vial Inj	Injectable	5063	26487

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
407	Streptomycin Inj. 1000 mg	Streptomycin Inj. 1000 mg	Injectable	1000	8000
408	Streptomycin Inj. 500 mg	Streptomycin Inj. 500 mg	Injectable	1000	8000
409	Streptomycin Inj. 750 mg	Streptomycin Inj. 750 mg	Injectable	1000	400000
410	Succinyl Choline Chloride 50mg/ml Inj 10ml Vial	Succinyl Choline Chloride 50mg/ml Inj 10ml Vial	Injectable	17316	428813
411	Suxamethonium Hydrochloride 50mg/ml	Inj. Suxamethonium Chloride 50 mg/ml - 2 ml Ampoule	Injectable	68094	15961234
412	Tecoplanin 600 mg Inj	Tecoplanin 600 mg Inj	Injectable	1000	1134000
413	Teicoplanin 200mg Inj	Teicoplanin 200mg Inj	Injectable	1373	192150
414	Teicoplanin 400mg Inj	Teicoplanin 400mg Inj	Injectable	2723	592307
415	Tenecteplase 20mg injection	Inj. Tenecteplase 20mg kit	Injectable	1000	19600000
416	Tenecteplase 40mg	Inj. Tenecteplase 40mg Vial	Injectable	3715	74556518
417	Tenecteplase 40mg Injection	Inj. Tenecteplase 40mg kit	Injectable	1000	19600000
418	Terlipressin Acetate 1mg/10ml 10ml ampoule Injection	Terlipressin Acetate 1mg/10ml 10ml ampoule Injection	Injectable	5625	2250000
419	Tetanus Immunoglobulin Human 250 I.U./1ml Inj vial	Tetanus Immunoglobulin Human 250 I.U./1ml Inj vial	Injectable	1000	693000
420	Tetanus Immunoglobulin Human 500 I.U./1ml Inj vial	Human Tetanus Immunoglobulin 500 I.U./1ml Inj vial	Injectable	1000	1197040
421	Tetanus Toxoid (Adsorbed)	Tetanus Toxoid DPAP - Each 0.5 ml human dose contains:tetanus toxoid $\geq$ LF, Adsorbed on aluminium phosphate $\geq$ 1.5 mg(AIPO ₄) Thiomersal 0.01% as preervative (vaccine fulfils the I.P. requirement for Tetanus toxoid (Adsorbed) 0.5 ml Ampoule	Injectable	18549000	132959232
422	Tetanus Toxoid 5 ml Vial	Tetanus Toxoid Inj 5ml Vial	Injectable	72383	1295531
423	Tetanus Toxoid Inj 0.5ml amp	Tetanus Toxoid Inj 0.5ml amp	Injectable	179325	1220127

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
424	Thiamine (Vitamin B1) 200mg/2ml Inj	Thiamine (Vitamin B1) 200mg/2ml Inj	Injectable	92273	3188938
425	Thiamine Hcl Inj 100mg/ml 10ml vial	Thiamine Hcl Inj 100mg/ml 10ml vial	Injectable	5625	393750
426	Thiamine Injection 100 mg	Thiamine Injection 100 mg contains Thiamine Hydrochloride 100mg, Benzyl Alcohol 2% w/v, Water fr Injection q.s., 2 ml Ampoule	Injectable	82053	3111450
427	Thiopentone Sodium 0.5gm Inj	Thiopentone Sodium 0.5gm Inj	Injectable	13709	403162
428	Thiopentone Sodium 1gm Inj	Thiopentone Sodium 1gm Inj	Injectable	16308	865172
429	Thrombin 2 ml + Fibrinogen 2 ml Fibrin Sealant	Should contain Human Fibrinogen and Human Thrombin, adjunct to hemostasis for use in patients undergoing surgery, when no control of bleeding by standard surgical techniques.Shelf life -2years Volume:2ml	Injectable	1000	11340000
430	Tigecycline 50 mg Injection	Injection Tigecycline 50 mg	Injectable	10688	2265750
431	Tigicycline 50mg Inj	Tigicycline 50mg Inj	Injectable	4613	2174406
432	Tirofiban 50mcg/ml Inj 100ml bottle	Tirofiban 50mcg/ml Inj 100ml bottle	Injectable	1000	2528000
433	Tobramycin (TOB)	EMIT. Drug labelled with G6PDH competes for antibody. G6PDH conversion of NAD---NADH	Injectable	1000	179200
434	Tramadol 50mg/ml Inj 1ml amp	Tramadol 50mg/ml Inj 1ml amp	Injectable	187538	400580
435	Tramadol Inj. 50mg/ml	Tramadol 50mg/ml Inj 2ml amp	Injectable	3202803	6078151
436	Tranexamic Acid 500mg/5ml Inj	Tranexamic Acid 500mg/5ml Inj	Injectable	376416	2131117
437	Trastuzumab 440mg/50ml	Trastuzumab 440mg/50ml	Injectable	1431	12592800
438	Triamcinolone 40 mg Injection	Inj. Triamcinolone 40 mg / ml	Injectable	1000	144800
439	Trypan Blue Ophthalmic Solution 0.06% w/v (0.6 mg/ml) 1ml vial	Trypan Blue Ophthalmic Solution 0.06% w/v Each mL contains: 0.6 mg trypan blue 1ml vial	Injectable	4500	181008
440	Ulinastatin 100000 IU Inj	Ulinastatin 100000 IU Inj	Injectable	1000	1559920
441	Valethamate Bromide Inj 8mg/ml	Valathamide Bromide 8mg/ml Inj	Injectable	27956	178920

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
442	Vancomycin 1gm Inj	Vancomycin 1gm Inj	Injectable	61875	3248685
443	Vancomycin HCL 500mg Inj	Vancomycin HCL 500mg Inj	Injectable	39713	1273024
444	Vancomycin inj. 1gm	Inj. Vancomycin 1 gm Vial	Injectable	5400	283522
445	Vancomycin inj. 250mg	Inj. Vancomycin 250 mg, Vial	Injectable	33291	684463
446	Vancomycin inj. 500mg	Inj. Vancomycin 500 mg, Vial	Injectable	1000	38286
447	Vasopressin Injection 20 units/ml 1ml amp	Vasopressin Injection 20 units/ml 1ml amp	Injectable	6188	742500
448	Vecuronium Bromide 10mg/10ml Inj 10ml amp	Vecuronium Bromide 10mg/10ml Inj 10ml amp	Injectable	30875	1878652
449	Vecuronium Bromide 4mg Inj	Vecuronium Bromide 4mg Inj	Injectable	126338	2448926
450	Vecuronium Bromide 4mg/2ml	Inj Vecuronium Bromide 4mg/2ml, Lyophilised Powder Vial	Injectable	28944	926208
451	Verapamil Inj 5mg/2ml	Inj. Verapamil 5mg/2ml, 2 ml Ampoule	Injectable	1782	2851
452	Vitamin A 1,00,000 I.U. Inj 1ml amp	Vitamin A 1,00,000 I.U. Inj 1ml amp	Injectable	1000	3200
453	Vitamin B Complex NFI Inj 10ml vial	Vitamin B Complex NFI Inj 10ml vial	Injectable	88425	713059
454	Vitamin B Complex with Vitamin B12 Injection 3ml ampoule	Each 3ml contains Thiamine Hydrochloride IP 100mg, Pyridoxine Hydrochloride IP 100mg, cyanocobalamin IP 1000mcg, riboflavine Sodium Phosphate IP5mg, Nicotinamide IP.100mg, D-Panthenol IP 50mg , Benzyl Alcohol IP 0.9% v/v , Water for Injection IP Q.S.I.M/I.V drip	Injectable	117450	1033560
455	Vitamin K Inj 1mg/ml Inj (Phytonadione) 0.5ml Amp	Vitamin K Inj 1mg/ml Inj (Phytonadione) 0.5ml Amp	Injectable	58613	529857
456	Vitamin K Inj. (Menadione) 10mg/ml Inj 1ml amp	Vitamin K Inj. (Menadione) 10mg/ml Inj 1ml amp	Injectable	171225	920506
457	Xylocaine 2% with Adrenaline for LA	Should contain xylocaine 2% solution for injection in vial with Adrenaline 1:1,00,000 and 1: 2,00,000 for dental use	Injectable	1000	40000
458	Xylocaine plain	should contain only xylocaine 2% solution in vial without any	Injectable	1000	40000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		vasoconstrictor for dental use. Should follow ISO/ISI standards			
459	Zoledronic Acid 4mg/ 100ml	Inj. Zolendronic Acid 4mg/ 100ml	Injectable	1161	185760
460	Zoledronic Acid Powder for inj 4mg	Inj. Zolendronic Acid 4mg/ 100ml Vial	Injectable	1431	286200

Appendix B: Checklist

(Mandatory Documents to be uploaded online in the EOI)

For the avoidance of any confusion, scanned copies of the above-mentioned documents shall be uploaded online on the Official Website on or prior to the EOI Due Date.

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
1	Copy of certificate of incorporation/registration along with charter documents, and other registration documents according to the nature of entity	Yes / No	
2	Pan Card Details	Yes / No	
3	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	
4	Copy of manufacturing drug license with product list duly approved by the Licensing Authority/ State drug authority for each and every product quoted as per specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license	Yes / No	
5	World Health Organization-Good Manufacturing Practice certificate with either product list or COPP	Yes / No	
6	Copy of permission from DCGI for “New drug & Fixed Dose Combination”	Yes / No	
7	Market Standing Certificate as issued by Central or State Licensing Authority for relevant period against quoted Drugs	Yes / No	

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
8	Non-Conviction Certificate issued by Licensing Authority.	Yes / No	
9	Annexure-1 (Technical Specifications and Compliance)	Yes / No	
11	Annexure-2 (Undertaking by EOI Respondent)	Yes / No	
12	Annexure-3 (Proforma for Production and Sale Statement)	Yes / No	
13	Annexure-4 (Details of Manufacturing Unit)	Yes / No	
14	Annexure-5 (Details of Items Quoted with Drug Code)	Yes / No	
15	Annexure-6 (Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2023-24, 2024-25 and 2025-26) certified by the Statutory Auditor or Chartered Accountant.	Yes / No	
16	Annexure-7 (Format for Power of Attorney for signing of EOI)	Yes / No	
17	Annexure-8 (Affidavit for Blacklisting)	Yes / No	
18	Annexure-9 (Litigation Affidavit)	Yes / No	
19	Annexure-10 (Mandate Form)	Yes / No	
20	Annexure -11 Delivery and Supply Capability	Yes / No	
21	Annexure-12 Respondent Classification	Yes / No	
22	Import Export Certificate (IEC Code) for Importer	Yes / No	
23	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	

Annexure 1: Technical Specifications and Compliance

Item Name: Following are the minimum requirements. Products offered must meet these parameters herein.

Sr. No	Item Name	Technical specification s/ composition of tender enquiry	Compliance on each parameter with detailed substantiation how the offered product meets the requirement.	If Column B=C (write Yes or No)	Generic Name / Brand Name (only for Importer)	Drug Mfg. License (Form 25 or 28 & 26)/ Medical devices/ Import License (Form 10 & 41)	MSM E/ SSI	Remarks, if any
	A	B	C	D	E	F	G	H

Note:

- Pharmacopoeia standards IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation quoted as per the provisions of the Applicable Laws.
- Active ingredient used in formulation of item quoted shall be of mentioned Pharmacopoeia quality & Specifications.

Sign

Stamp

Date

Annexure-2: Undertaking by EOI Respondent

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
Near CSMT Railway Station, Mumbai 400001 (Maharashtra)

Subject: EOI for the [*****]

Dear Sir,

With reference to your EOI dated _____, I, having examined the document and understood its contents, hereby submit my/our EOI for the aforesaid [*****]. The EOI is submitted voluntarily and without reservation, solely for market assessment purposes.

1. I/ We acknowledge that MMGPA will be relying on the information provided in the EOI and the documents accompanying such EOI, and we certify that all information provided therein is true and correct; nothing has been omitted which renders such information misleading; and all documents accompanying such EOI are true copies of their respective originals.
2. I/ We shall make available to MMGPA any additional information it may find necessary or require supplementing or authenticate the EOI.
3. I/ We declare that:
 - a) I/ We have examined and have no reservations to the EOI, including any Addendum / Corrigendum issued by MMGPA.
 - b) I/ We do not have any conflict of interest in accordance with the EOIs; and
 - c) I/We have not directly or indirectly or through an agent engaged or indulged in any unethical practice, as defined in the EOI, in respect of any tender or request for proposal issued by or any agreement entered into with MMGPA or any other public sector enterprise or any government, Central or State.
4. I/ We understand that this EOI is purely for market analysis purpose and you may not issue any following tender or empanelment process after this.
5. I/ We certify that we the Annual Turnover and Net Worth given by us is correct to the best of our knowledge.
6. I/ We certify that in regard to matters other than security and integrity of the country, we or any of our associates have not been convicted by a Court of Law or indicted or adverse orders passed by a regulatory authority which could cast a doubt on our ability to undertake the Contract or which relates to a grave offence that outrages the moral sense of the community.
7. I/ We further certify that in regard to matters relating to security and integrity of the country, we or any of our associates have not been charge-sheeted by any agency of the Government or convicted by a Court of Law.
8. I/ We further certify that no investigation which materially affects regulatory compliance or manufacturing/import operations is pending either against us or against our associates or against our CEO or any of our directors/ managers/ employees / Partners /Trustees.
9. I/We further certify that we or any of our Associates are not barred by the Central Government/ State Government or any entity controlled by it, from participating in any supply of drugs contract, and no bar subsists as on the EOI Due Date.

10. The power of attorney for signing of EOI, as per format provided at Annexure-6 of the EOI, is also enclosed.

In witness thereof, I/we submit this EOI under and in accordance with the terms of the EOI.

Yours faithfully,

Date:

(Signature, Name and designation of the Authorised signatory)

Place:

(Name and seal of Responder)

Annexure-3: Proforma for Production and Sale Statement

Name of the EOI Respondent entity:

Sr. No.	Year	Name and full Address of the Purchaser	Purchasing Entity (Gov./Semi Gov./Reg. under Trust)	Name of the Product	Purchase Order No. & Date	Purchase Order Quantity	Batch No.		PO Copy enclosed on Pg. No.
							Manufactured Qty	Sold Qty	
1	2023-24								
2	2024-25								
3	2025-26								

Add rows as per requirement.

Note:

1. In support of above statement, enclose the copies of supply orders and client's satisfactory certificates. All purchase orders should be enclosed in the serial as per the data provided in table above.
2. In case of importer, sold quantity shall be provided, production and manufactured good details may not be provided-
3. All the data of the bidding entity, as provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.
4. The issuer of this certificate must ensure that the above information/details are related to the bidding entity only.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure 4: Details of Manufacturing Unit

(The details of manufacturing facility to be furnished)

- 1 Name of the EOI Respondent :
- 2 Registered Office Address :
- 3 Manufacturing Unit Address :
- 4 PAN :
- 5 GST No. :
- 6 Manufacturing License No.:
- 7 Date of Issue :
- 8 Valid up to / Retention :
- 9 Issued by (SLA / CLA) :
- 10 WHO-GMP / Equivalent Certification:
 - a. Certifying Authority
 - b. Certificate Validity
- 11 Details of Installed Manufacturing Capability (Indicative)

Type	Indicative Capability Details
Tablets	
Capsules	
Injections	
IV Fluids	
Sterile Powders	
Liquids / Syrups	
Ointments / Creams	
Other (specify)	

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Details of Installed Production Capacity for 30 days
(In Terms of Unit Packs)

Tablets :

Capsules:

General:

Beta-Lactum :

Injection

Ampoules :

Vials :

I.V.Fluids :

Sterile Powder:

Liquids

Suspension :

Syrups :

Drops :

Ointment :

Powders :

Antiseptics/

Disinfectants :

Name & designation of the authorized signatory:

Specimen signature of the authorized Signatory:

*The details of manufacturing unit should be for the premises where drugs quoted are actually manufactured.

THE DETAILS OF FACTORY PREMISES

Person In-charge of Factory

Name :

Phone No. :

Mobile No. :

Nearest Landmark of Factory:

Layout

Km from Airport :

Name of the Airport and City:

Km from Railway Station :

Name of the Railway Station :

Km from Bus Stand :

Name of the Bus Stand :
And City

All the data provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-4 (A): Proof of Distribution Network

A. Distribution / Logistical Details

S.No	Particulars	Details
1	Whether distribution/logistics arrangement exists	Yes / No
2	Nature of arrangement (Own / Third-party / Proposed)	
3	Broad geographic coverage	
4	Presence in Maharashtra (if any)	Yes / No
5	Any other relevant details	

B. Authorised Distributors / Logistic Partners (If Applicable)

Sr. No.	Name	Address
1		
2		

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Annexure-5: Details of Items Quoted with Drug Code

1. Name of the firm:
2. Address as given in drug licence:
3. Drug Licence No. in Form 25 &28:
4. Import Licence No. :
5. Date of issue:
6. Validity:
7. Non-conviction Certificate obtained on:
8. Market standing certificate obtained on:
9. Details of endorsement for all products:

Sr. No.	Drug name	Specifications IP/BP/USP	Date of endorsement obtained from State Drugs Commissioner	Whether Endorsement is in Generic or Brand Name

Add As Many Rows as possible You Want to Add

(Additional column should be inserted asking date of permission from CDSCO, in case of all newly introduced drugs and Fixed dose combinations)

Annexure 6: Annual Turnover Statement for Three Years

M/s. is participating in Tender No..... Items details as per Below Table.

Sr. No. of Item (as per Appendix A)	Name of Item	Required Turnover (In Rs)
Total Required Turnover		

The Average Annual Turnover and Net Worth details of M/s _____ for participation under the Tender Document are given below and certified that the statement is true and correct.

Sr. No.	Year	Turnover (In Rs.)
1		
2		
3		
4		
Net Worth		
5	Net worth in the latest financial year preceding the Bid Due Date (positive/negative)	

“Net Worth” in case of Company shall mean the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

For other eligible entities, the Net Worth shall mean the amount derived by subtracting the liabilities from the assets as certified by the chartered accountant/statutory auditor having valid registration.

Note:

1. Certificate issued by a statutory auditor/chartered accountant along with audited financial statements confirming the average annual turnover of the Bidder during the stated financial years must be submitted on the letterhead of the statutory auditor/chartered accountant.
2. Provide supporting audited financial statements (Balance Sheets, Profit and Loss Statements, etc.) of the bidding entity.
3. The Net Worth of the bidder in the financial year immediately preceding the Bid Due Date should be positive.
4. “Turnover” for the purposes of this Tender Document shall mean the monetary value of goods sold by the Bidder.

Name, Membership number and signature of the Chartered Accountant:

UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature of Bidder (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name):

Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-7: Format for Power of Attorney for signing of EOI

(To be executed as an Affidavit on a Stamp paper of appropriate value)

Know all men by these presents, We, (name of the firm and address of the registered office) do hereby irrevocably constitute, nominate, appoint and authorize Mr. / Ms (Name), son/daughter/wife of..... and presently residing at, who is presently employed with us and holding the position of, as our true and lawful attorney (hereinafter referred to as the “**Attorney**”) to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental to submission of our EOI for the [*****], proposed or being developed by the [*****] (the “**Purchaser**”) including but not limited to signing and submission of all applications, EOIs and other documents and writings, participate in Responders' and other conferences and providing information / responses to MMGPA, representing us in all matters before MMGPA, signing and execution of all contracts including the Contract and undertakings consequent to acceptance of our EOI, and generally dealing with MMGPA in all matters in connection with or relating to or arising out of our EOI for the said Contract and/or upon award thereof to us and/or till the entering into of the Contract with MMGPA.

AND we hereby agree to ratify and confirm and do hereby ratify and confirm all acts, deeds and things done or caused to be done by our said Attorney pursuant to and in exercise of the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the powers hereby conferred shall and shall always be deemed to have been done by us.

IN WITNESS WHEREOF WE, ..., THE
ABOVE-NAMED PRINCIPAL HAVE EXECUTED THIS POWER OF ATTORNEY ON
THIS
DAY OF, 20.....

For

(Signature, name, designation and address of person authorized by Board Resolution
in case of Firms/Company)/Partner in case of
Partnership Firms

Witnesses:

1.

2.

Notarised Person identified by me/personally appeared before me

/Signed before me/Attested/Authenticated* (*Notary to specify as applicable) (Signature, Name and Address of the Notary)

Seal of the Notary Registration Number of the Notary

Date__

Signature, name, designation and address of the Attorney)

Notes:

- The mode of execution of the Power of Attorney should be in accordance with the procedure, if any, laid down by the applicable law and the charter documents of the executants (s) and when it is so required, the same should be under common seal affixed in accordance with the required procedure.

Wherever required, the Responder should submit for verification the extract of the charter documents and documents such as a board or shareholders resolution/power of attorney in favour of the person executing this Power of Attorney for the delegation of power hereunder on behalf of the Responder.

- For a Power of Attorney executed and issued overseas, the document will also have to be legalized by the Indian Embassy and notarized in the jurisdiction where the Power of Attorney is being issued. However, the Power of Attorney provided by Responders from countries that have signed the Hague Legislation Convention, 1961 are not required to be legalized by the Indian Embassy if it carries a conforming Apostille certificate issued by the designated competent authority and has been notarized by the public notary.

Annexure-8: Undertaking for Non-blacklisting

(on Letterhead of the Respondent)

EOI reference No:E-290/MMGPA/ EOI for Injectables (2026-27)

1. I/We, (Name of the Responder), the Responder herein, has not been found guilty of malpractices, misconduct or Blacklisted/Debarred/ deregistered for the quoted product by any department of Govt. of Maharashtra or by any local authority and semi Govt. organization and other State Government/Central Government's organizations/ procurement corporation as on the date of submission EOI for the quoted items.

4. I/We undertake that I/we are not involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings.

Seal

Signature of Authorized Signatory

Date

Place

Verification

I, the above named [*Name of the Responder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure- 9: Litigation Affidavit

(on Non-judicial Stamp Paper of Rs.500/-)

EOI reference No:E-290/MMGPA/ EOI for Injectables (2026-27)

I _____ age _____ address (authorized signatory to sign the contract), hereby submit, vide this affidavit in truth, that I am the owner/authorized signatory of the bidding entity and I am submitting the documents in Envelope no.1 for the purpose of security of the contract. I hereby agree to the conditions mentioned below:-

1. I am liable for action under Bharatiya Nyaya Sanhita (BNS) for submission of any false/ fraudulent paper/information submitted in Envelope no.1
2. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if during contract period and any false information, false bill of purchases supporting proof of purchase, proof of testing submitted by my staff, subletting company or by myself, I will be liable for action under Bharatiya Nyaya Sanhita (BNS).
3. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if any paper is found false / fraudulent during contract period and even after the completion of contract (finalization of final bill).

Authorised Signature of Bidder

Seal of Company

Verification

I, the above named [*Name of the Bidder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure-10: Litigation Affidavit

01	Company Name	
02	Postal Address of the company with Telephone No., Fax No. and Mail address	
03	Name of the Managing Director/ Director/Manager Mobile No. /Phone No. E-mail address	
04	Name and designation of the authorized company official Mobile No. /Phone No. E-mail address	

Bank Details

01	Name of the Bank Branch Name & Address: Branch Code No. Branch Manager Mobile No. Branch Telephone no. Branch E-mail ID	
02	9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.	
03	IFSC code of the Branch	
04	Type of Account (Current/Savings)	
05	Account Number (as appear in cheque book)	

(in lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars)

I/We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold Maharashtra Medical Goods Procurement Authority, Mumbai. I have read the conditions of tender/ agreement entered and agree to discharge the responsibility expected of me/from the company as a tenderer/ successful bidder.

Date

Company Seal

Signature

Place

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address

Signature of the Authorized Official of the bank

Annexure 11: Delivery and Supply Capability

(To be submitted on the letterhead of the EOI Respondent)

This Annexure is intended to capture indicative information on the delivery readiness and supply capability of the EOI Respondent for the purpose of market assessment.

A. General Information

Name of the EOI Respondent: _____

Type (OEM / Authorized Importer): _____

Sr. No.	Parameter	Details
1	Average Production Lead Time (in days)	
2	Average Dispatch Time after production readiness (in days)	
3	Expected Delivery Timeline to Maharashtra (in days)	
4	Emergency Supply Capability (Yes/No, give details)	
7	Warehousing Facility in Maharashtra (Yes/No, location)	
8	Cold Chain Facility (if applicable)	
9	Logistics Arrangement (Own / Third-party / Hybrid)	
10	Any other relevant information	

Note: Submission of a physical Delivery Challan at the time of delivery is mandatory. The challan must bear the signature and seal of the authorized accepting authority; without such acknowledgment, the delivery shall not be treated as complete.

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____

Annexure 11 (a) : Delivery Acceptance Certificate

FINAL ACCEPTANCE CERTIFICATE

Date: / /2026.

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
St. George's Hospital Compound, Mumbai 400001
Maha.mmgsa2023@gmail.com

Subject: Acceptance Certificate for the supply of

Reference: Purchase Order No.

As per above mentioned reference purchase order, the said material has been received by this office / hospital in good condition & as per terms & condition of the purchase order. The details of the same are as follows;

Sr. No.	Particular(s)	Specific information
1	Name of Material Received	
2	Quantity as per Purchase Order	
3	Invoice Number with Date	
4	Batch Number(s) with Quantity	
5	Total Quantity Received	
6	Date of Receipt of Material	
7	Entry Taken in Stock Book	
8	Stock Book No.	
9	Page Number	
10	Name of the Supplier	
11	Name of the Manufacturer	
12	Address of the Manufacturer as per Invoice	
13	Material Received as per Technical Specifications mentioned in Purchase Order (YES/NO)?	

**This is certifying that, the above information is true on the basis of office record.

Name of Pharmacist/ Store In-charge;

Name of Office/ Hospital In-charge;

(Signature with Stamp)

(Signature with Stamp)

Date:

Place:

Mail id for Acceptance: maha.mmgsa2023@gmail.com

71 | Page

EOI for Tablet and Capsules

Annexure 12: Respondent Classification Details

(To be submitted on the letterhead of the EOI Respondent)

This Annexure captures classification details for MSME status, social category, and geographical presence.

A. Basic Details

Sr. No.	Parameter	Details
1	Name of EOI Respondent	
2	Type of Entity (Company / LLP)	
3	Nature (OEM / Authorized Importer)	

B. Classification Details

Sr. No.	Parameter	Details
1	MSME Status (Yes/No)	
2	MSME Registration Number	
3	SC/ST Ownership (Yes/No)	
4	Certificate Details	

C. Classification

Sr. No.	Classification Parameter	Select One
1	Location Classification	☐ Within Maharashtra ☐ Outside Maharashtra
2	MSME Category	☐ MSME (Within Maharashtra) ☐ MSME (Outside Maharashtra) ☐ Non-MSME
3	SC/ST Category	☐ SC/ST (Within Maharashtra) ☐ SC/ST (Outside Maharashtra) ☐ Not Applicable

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____